<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">104374</article-id><article-id pub-id-type="doi">10.7554/eLife.104374</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.104374.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Chemotherapy resistance due to epithelial-to-mesenchymal transition is caused by abnormal lipid metabolic balance</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Matsumoto</surname><given-names>Atsushi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3814-3299</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Inoko</surname><given-names>Akihito</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6739-2948</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Takuya</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Konishi</surname><given-names>Gen-Ichi</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hosoda</surname><given-names>Waki</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kojima</surname><given-names>Takahiro</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ohnishi</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ikenouchi</surname><given-names>Junichi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2936-3548</contrib-id><email>ikenouchi.junichi.033@m.kyushu-u.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00p4k0j84</institution-id><institution>Department of Biochemistry, Kyushu University Graduate School of Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02h6cs343</institution-id><institution>Department of Pathology, Aichi Medical University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Nagakute</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03kfmm080</institution-id><institution>Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Nagoya</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dqf9946</institution-id><institution>Department of Chemical Science and Engineering, Institute of Science Tokyo, Meguro-ku</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03kfmm080</institution-id><institution>Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Nagoya</named-content></addr-line><country>Japan</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03kfmm080</institution-id><institution>Department of Urology, Aichi Cancer Center Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Nagoya</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Wakana</surname><given-names>Yuichi</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057jm7w82</institution-id><institution>Tokyo University of Pharmacy and Life Sciences</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Campelo</surname><given-names>Felix</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04n0g0b29</institution-id><institution>Universitat Pompeu Fabra</institution></institution-wrap><country>Spain</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>01</month><year>2026</year></pub-date><volume>13</volume><elocation-id>RP104374</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-10-22"><day>22</day><month>10</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-10-22"><day>22</day><month>10</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.10.22.619604"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-18"><day>18</day><month>12</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.104374.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-11-28"><day>28</day><month>11</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.104374.2"/></event></pub-history><permissions><copyright-statement>© 2024, Matsumoto, Inoko et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Matsumoto, Inoko et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-104374-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-104374-figures-v1.pdf"/><related-article related-article-type="commentary" ext-link-type="doi" xlink:href="10.7554/elife.110231" id="ra1"/><abstract><p>Invasive cancer is defined by the loss of epithelial cell traits resulting from the ectopic expression of epithelial–mesenchymal transition (EMT)-related transcription factors such as Snail. Although EMT is known to impart chemoresistance to cancer cells, the precise molecular mechanisms remain elusive. We found that Snail expression confers chemoresistance by upregulating the cholesterol efflux pump ABCA1 as a countermeasure to the excess of cytotoxic free cholesterol relative to its major interaction partner in cellular membranes, sphingomyelin. This imbalance is introduced by the transcriptional repression of enzymes involved in the biosynthesis of sphingomyelin by Snail. Inhibiting esterification of cholesterol, which renders it inert, selectively suppresses growth of a xenograft model of Snail-positive kidney cancer. Our findings offer a new perspective on lipid-targeting strategies for invasive cancer therapy.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cholesterol</kwd><kwd>epithelial–mesenchymal transition</kwd><kwd>sphingomyelin</kwd><kwd>cancer</kwd><kwd>Snail</kwd><kwd>chemotherapy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/004rtk039</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>21444781</award-id><principal-award-recipient><name><surname>Ikenouchi</surname><given-names>Junichi</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hhkn466</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP25H00994</award-id><principal-award-recipient><name><surname>Ikenouchi</surname><given-names>Junichi</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hhkn466</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP25H01325</award-id><principal-award-recipient><name><surname>Ikenouchi</surname><given-names>Junichi</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hhkn466</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP25K22454</award-id><principal-award-recipient><name><surname>Ikenouchi</surname><given-names>Junichi</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hhkn466</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP22KJ2374</award-id><principal-award-recipient><name><surname>Matsumoto</surname><given-names>Atsushi</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hhkn466</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP25K18465</award-id><principal-award-recipient><name><surname>Matsumoto</surname><given-names>Atsushi</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00097mb19</institution-id><institution>Japan Science and Technology Agency</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.52926/JPMJFR204L</award-id><principal-award-recipient><name><surname>Ikenouchi</surname><given-names>Junichi</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y123g31</institution-id><institution>Takeda Science Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ikenouchi</surname><given-names>Junichi</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00krdxg91</institution-id><institution>Ono Medical Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ikenouchi</surname><given-names>Junichi</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Lipid imbalance triggered by Snail-driven epithelial–mesenchymal transition creates a cholesterol-dependent vulnerability that can be therapeutically targeted to overcome chemoresistance in cancer.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Metastatic cancer, characterized by the spread of tumor cells to distant organs, remains a major challenge in cancer treatment due to its high mortality rate. Metastasis involves a series of biological events, such as acquisition of cancer stem cell characteristics, tumor–microenvironment interactions, alterations in cell metabolism and resistance to chemotherapy, that are mediated by epithelial–mesenchymal transition (EMT) (<xref ref-type="bibr" rid="bib25">Nieto et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Lambert and Weinberg, 2021</xref>; <xref ref-type="bibr" rid="bib41">Zheng et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Fischer et al., 2015</xref>). Transcription factors driving EMT (EMT-TFs), including Snail, Slug, and Twist, that are ectopically expressed in invasive cancers were initially thought to promote invasion and metastasis by suppressing the expression of adhesion molecules in cancer cells. However, since E-cadherin-mediated adhesion is essential for cell survival after metastasis (<xref ref-type="bibr" rid="bib27">Padmanaban et al., 2019</xref>), invasive cancer cells do not undergo complete EMT but rather sustain a hybrid state with both epithelial and mesenchymal (hybrid E/M) characteristics. In a mouse model of pancreatic carcinoma and breast cancers where key EMT-TFs were deleted, the suppression of EMT did not alter the appearance of systemic dissemination or metastasis but rather contributed to increased sensitivity to anticancer drugs (<xref ref-type="bibr" rid="bib41">Zheng et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Fischer et al., 2015</xref>). Therefore, an in-depth understanding of the molecular mechanisms of resistance to anticancer drugs conferred by EMT-TFs is an essential prerequisite for devising effective therapeutic interventions (<xref ref-type="bibr" rid="bib9">Davis et al., 2014</xref>). It was recently reported that expression of a Rho family GTPase, RHOJ, is upregulated in cancer cells undergoing EMT and that its activation enhances the DNA damage response, which enables tumor cells to efficiently repair chemotherapy-induced DNA damage (<xref ref-type="bibr" rid="bib10">Debaugnies et al., 2023</xref>). Here, we investigated EMT-dependent acquisition of resistance to anticancer agents that do not directly cause DNA damage, such as those targeting the ERK signaling pathway, and found that expression of EMT-TFs causes metabolic alterations of sphingomyelin, resulting in ectopic induction of drug efflux transporter expression and conferring chemotherapy resistance to cancer cells.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Snail-induced ABCA1 expression confers chemoresistance to hybrid E/M cells</title><p>Renal cell carcinoma (RCC) is notorious for the lack of sensitivity to chemotherapy (<xref ref-type="bibr" rid="bib23">Makhov et al., 2018</xref>), but the underlying mechanisms are not elucidated. Nitidine chloride (NC) holds promise as a drug treatment against RCC as it was shown to have a pro-apoptotic effect on RCC and inhibit tumor growth by suppressing the ERK signaling pathway in a xenograft model (<xref ref-type="bibr" rid="bib7">Cui et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Fang et al., 2014</xref>). However, in human lung adenocarcinoma cells, NC efficacy was inversely correlated with the expression level of the drug transporter ABCA1: cancer cells with downregulated ABCA1 were more sensitive to NC treatment (<xref ref-type="bibr" rid="bib18">Iwasaki et al., 2010</xref>). Therefore, we wondered whether ABCA1 could also confer NC resistance in RCC. We treated five different RCC cell lines with a combination of NC and an ABCA1 inhibitor cyclosporin A (CsA). Antiproliferative effect of NC was significantly enhanced in the presence of CsA for three lines among five, Caki-1, 786-O, and A498 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). These cells consistently expressed higher levels of ABCA1 compared to the nonresponsive cells (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>), suggesting the acquisition of ABCA1-mediated drug resistance. Notably, ABCA1 expression was positively correlated with expression of the EMT-TF Snail in the RCC cell lines (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>). To investigate the clinical relevance of ABCA1 upregulation in cancers, we analyzed <italic>ABCA1</italic> expression in cancer using the UCSC Xena platform. Comparative <italic>ABCA1</italic> expression data of both normal tissue and primary tumors were available for 24 cancer subtypes in the GDC TCGA database. In addition to glioblastoma and head and neck cancer, all three types of renal cancers (clear cell carcinoma [ccRCC], chromophobe carcinoma, and papillary cell carcinoma) exhibited significant <italic>ABCA1</italic> upregulation in tumor (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>), indicating that ABCA1 upregulation frequently occurs in clinical renal cancers.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Ectopic expression of Snail confers epithelial cells nitidine chloride (NC) resistance via induction of ABCA1 expression.</title><p>(<bold>A</bold>) Enhancement of growth inhibitory effect of NC on human renal carcinoma cells by co-treatment with an ABCA1 inhibitor cyclosporin A (CsA). Cells were grown with or without 20 μM NC and 10 μM CsA for 24 h, and cell number was determined with CCK-8. Fold change in cell number by NC was shown as relative to controls without NC. Results are shown as mean of at least four independent experiments ± SD (Tukey–Kramer’s multiple comparison test). <italic>n</italic> = 4 (KMRC-3,786-O,A498), 5 (Caki-1) or 6 (TUHR14TKB). (<bold>B–E</bold>) Immunoblot analysis of whole-cell lysate of human renal carcinoma cell lines. A representative result from three independent experiments is shown (<bold>B</bold>). Quantitative analyses of Snail (<bold>C</bold>) and ABCA1 (<bold>D</bold>) expression are presented. A scatter plot illustrating the correlation between ABCA1 and Snail expression levels is also shown (<bold>E</bold>). Quantitative data are shown as mean of three independent experiments ± SD (Tukey–Kramer’s test). (<bold>F</bold>) Comparison of <italic>ABCA1</italic> expression between normal tissue and primary tumor of indicated subtypes of renal cancers analyzed using UCSC Xena (<ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net/">https://xenabrowser.net/</ext-link>). Bars indicate means (Welch’s <italic>t-</italic>test). (<bold>G</bold>) Immunohistochemistry of a surgically extracted renal tissue from a patient with Fuhrman grade 3 primary ccRCC, indicating upregulation of ABCA1 in the lesion site. The ABCA1 staining was verified by the accumulation of known signals in renal tubules and glomeruli in normal tissue (<xref ref-type="bibr" rid="bib40">Yang et al., 2010</xref>). Scale bars, 250 μm (left), 50 μm (right). (<bold>H</bold>) Quantification of ABCA1 signal from surgically extracted renal tissues from three patients for each Fuhrman grade (Tukey–Kramer’s test; see also <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). (<bold>I</bold>) Phase-contrast images of EpH4 wild-type cells (top) and Snail-overexpression cells (bottom, EpH4-Snail). Scale bars, 50 μm. (<bold>J</bold>) Immunofluorescence images of EpH4 and EpH4-Snail cells. The cells were fixed. Scale bars, 20 μm. (<bold>K</bold>) Acquisition of NC resistance by exogenous expression of Snail in EpH4 cells and enhancement of 20 μM NC effect on EpH4-Snail cells by co-treatment with 10 μM CsA. Data are presented as in (<bold>A</bold>) (<italic>n</italic> = 3, Tukey–Kramer’s test). (<bold>L</bold>) Immunoblot analyses of whole-cell lysates of EpH4, EpH4-Snail, E-cadherin KO, and α-catenin KO EpH4 cells. Quantitative analyses of ABCA1 expression is also shown (<italic>n</italic> = 3, Dunnett”s test). (<bold>M</bold>) Immunofluorescence images of EpH4 and EpH4-Snail cells. Cells were fixed with MeOH. Scale bars, 20 μm. (<bold>N, O</bold>) Immunoblot analyses of whole-cell lysates of MDCK II cells (<bold>N</bold>) expressing KRAS G12V treated with 5 μg/ml TGFβ for 0, 3, and 8 days and human esophageal carcinoma cell lines TE-15 and TE-8 (<bold>O</bold>). Graphs on the bottom show analyses from three biological replicates (Tukey–Kramer’s test [<bold>N</bold>] and Student’s <italic>t</italic>-test [<bold>O</bold>]). Phase-contrast images are also shown on the top (<bold>O</bold>). Scale bars, 50 μm.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original raw data for the immunoblot images shown in <xref ref-type="fig" rid="fig1">Figure 1B, L, N and O</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-104374-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Labeled full blot images for the immunoblot images shown in <xref ref-type="fig" rid="fig1">Figure 1B, L, N and O</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-104374-fig1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Cancer types that exhibit tumor-specific upregulation of ABCA1 transcription.</title><p>(<bold>A–C</bold>) Comparison of mRNA transcription of <italic>ABCA1</italic> (<bold>A, B</bold>) and <italic>Snail</italic> (<bold>C</bold>) in different cancer types. Expression data from GDC TCGA database were analyzed using UCSC Xena platform (<ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net/">https://xenabrowser.net/</ext-link>) (Welch’s <italic>t-</italic>test).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Comparison of ABCA1 expression in different progression grades of kidney cancer cases.</title><p>Immunohistochemistry of surgically extracted renal tissues from patients with Fuhrman grade 13 primary ccRCC, indicating elevation of ABCA1 signal at the lesion site of higher-grade ccRCC. All samples were collected from independent patients. The ABCA1 staining was verified by the accumulation of known signals in renal tubules and glomeruli in normal tissues (<xref ref-type="bibr" rid="bib40">Yang et al., 2010</xref>). Scale bars, 100 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig1-figsupp2-v1.tif"/></fig></fig-group><p>To examine whether the enrichment of ABCA1 protein in malignant cancer cells is detectable in clinical cases, we conducted immunohistochemical analysis on surgical specimens taken from patients with primary ccRCC. The findings showed that ABCA1 was upregulated at the lesion site of high-grade ccRCC (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). This clinical data aligns with our cellular experimental results, as Snail expression is known to be upregulated in high-grade ccRCC. Upon detailed comparison among grades, ABCA1 signal was more prominent in the patients with the high-grade classification (<xref ref-type="fig" rid="fig1">Figure 1H</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), suggesting that ABCA1 could serve as a marker for high-grade ccRCC. Xena analysis also revealed significantly higher expression of <italic>Snail</italic> in ccRCC, also supporting the idea that ABCA1 upregulation is correlated with exogenous Snail expression (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p><p>Our results suggest the correlation between chemoresistance and Snail expression level. In order to clarify whether Snail expression alone can confer resistance to anti-cancer drugs in epithelial cells, Snail was ectopically expressed in normal epithelial cells, and we investigated changes in resistance to anticancer drugs. Overexpression of Snail in a mouse mammary gland epithelial cell line EpH4 abolishes transcription of various genes involved in cell–cell adhesion including E-cadherin (<xref ref-type="fig" rid="fig1">Figure 1I</xref>; <xref ref-type="bibr" rid="bib4">Cano et al., 2000</xref>; <xref ref-type="bibr" rid="bib3">Batlle et al., 2000</xref>; <xref ref-type="bibr" rid="bib16">Ikenouchi et al., 2003</xref>). EpH4-Snail cells exhibited coexistence of the mesenchyme-specific intermediate filament Vimentin and the epithelium-specific Cytokeratin-18 (<xref ref-type="fig" rid="fig1">Figure 1J</xref>), which is a typical feature of a hybrid E/M state of cancer cells. The hybrid E/M EpH4-Snail cells were significantly more resistant to NC than parental EpH4 cells (<xref ref-type="fig" rid="fig1">Figure 1K</xref>). Consistent with the results of kidney cancer cell lines, this resistance was canceled by CsA (<xref ref-type="fig" rid="fig1">Figure 1K</xref>), and upregulation of ABCA1 expression was also observed in EpH4-Snail cells (<xref ref-type="fig" rid="fig1">Figure 1L and M</xref>). Consistent with the resistance to the antitumor agent, ABCA1 mainly localized to the plasma membrane in EpH4-Snail cells (<xref ref-type="fig" rid="fig1">Figure 1M</xref>). We also examined another model with a different cell line. In MDCK II, a canine kidney epithelial cell line, TGF-β treatment induced EMT under the expression of the oncogenic KRAS-G12V mutant (<xref ref-type="bibr" rid="bib2">Arner et al., 2019</xref>). The upregulation of ABCA1 expression was also observed in this transient hybrid E/M model (<xref ref-type="fig" rid="fig1">Figure 1N</xref>), suggesting that similar mechanisms to those in EpH4-Snail are also at play in kidney cell EMT. Notably, induction of ABCA1 expression requires a longer period of treatment with TGF-β (day 8) than Snail induction (day 3), indicating that ABCA1 is upregulated in response to cellular alteration by Snail but not induced directly by TGF-β signaling. Furthermore, in comparison between human esophageal cancer cell lines (<xref ref-type="bibr" rid="bib36">Szlasa et al., 2020</xref>), Snail-positive TE-8 cells exhibited higher expression of ABCA1 than Snail-negative TE-15 (<xref ref-type="fig" rid="fig1">Figure 1O</xref>). These results suggest that the induction of ABCA1 by ectopic expression of Snail occurs regardless of cellular background.</p></sec><sec id="s2-2"><title>Intracellular cholesterol accumulation drives ABCA1 expression in hybrid E/M cells</title><p>Then how does Snail induce ABCA1 expression, since as a transcriptional repressor it is incapable of doing so directly? Upregulation of ABCA1 was not observed in either E-cadherin or α-catenin KO cells (<xref ref-type="fig" rid="fig1">Figure 1L</xref>), indicating that ABCA1 induction is driven as a specific response to a fundamental change in cellular state induced by Snail overexpression, not an ancillary effect of disrupting either cell-cell adhesion or apical-basal polarity. Generally, ABCA1 is a transporter for the efflux of cholesterol out of the cell when there is an excess of cholesterol in the cell and ABCA1 upregulation in response to excess loading of cholesterol is mediated by sterol-activated nuclear receptors, LXRs (<xref ref-type="bibr" rid="bib15">Ignatova et al., 2013</xref>). Aside from the cholesterol-LXRs regulatory axis, it was recently reported that ABCA1 expression in epithelial cells is regulated via FOXO3a and c-Myc (<xref ref-type="bibr" rid="bib13">Frechin et al., 2015</xref>). Activation of FAK/PI3K/Akt signaling depending on cell crowding state downregulates ABCA1 expression via phosphorylation of FOXO3a, a positive transcriptional regulator of ABCA1 (<xref ref-type="bibr" rid="bib13">Frechin et al., 2015</xref>). We found that the phosphorylation level of FOXO3a at S453 tended to be lower in EpH4-Snail cells than in wild-type EpH4 cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). However, since downregulation of Akt signaling by treatment with inhibitors of its activators GSK2334470 (PDK1), LY294002 (PI3K), and Wortmannin (PI3K) did not induce ABCA1 expression in wild-type EpH4 cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), FOXO3a would not be responsible for ABCA1 expression in EpH4-Snail cells. Although ABCA1 expression is also downregulated by c-Myc in breast cancer, no remarkable difference in c-Myc expression was observed between EpH4 and EpH4-Snail cells, indicating that c-Myc is not likely involved in ABCA1 expression in EpH4-Snail cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Therefore, we next pursued in detail the possibility that LXRs induce ABCA1 in EpH4-Snail cells. Immunofluorescence microscopy revealed that LXRs are highly accumulated in the nuclei of EpH4-Snail cells, suggesting that ABCA1 upregulation could be mediated by LXRs (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Consistently, treatment with an LXR inhibitor GSK2033 abolished ABCA1 expression to an undetectable level in EpH4-Snail cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). GSK 2033 treatment also canceled NC resistance (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), suggesting that cholesterol efflux system activated by LXR is important for acquisition of chemoresistance. However, EpH4-snail cells did not show enhanced sensitivity to NC treatment even when ABCA1 was depleted by knockout (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Given that CsA inhibits other isoforms of ABC transporters (<xref ref-type="bibr" rid="bib6">Cserepes et al., 2004</xref>), other LXR-regulated efflux pumps may also contribute to chemoresistance.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Alteration of cellular cholesterol distribution induces ABCA1 expression in hybrid E/M cells.</title><p>(<bold>A</bold>) Immunofluorescence images of cells stained with the LXRα+β antibody. Scale bars, 10 μm. Cells were fixed with 4% PFA. Comparison of the abundance of LXR is also shown (bottom). LXR signal intensity overlapped with DAPI signals was determined for three independent fields of view (Student’s <italic>t</italic>-test). (<bold>B</bold>) Immunoblot analyses of whole-cell lysates of EpH4-Snail cells treated with 1 μM GSK-2033 for 24 h (<italic>n</italic>=4, Student’s <italic>t-</italic>test). (<bold>C</bold>) Enhancement of growth inhibitory effect of nitidine chloride (NC) by co-treatment with an LXR inhibitor GSK2033. Cells were treated with or without 1 μM GSK2033 for 24 h, then cultured with or without 20 μM NC and 1 μM GSK2033 for 24 h, and cell number was determined with CCK-8. Fold change in cell number by NC was shown as relative to controls without NC (<italic>n</italic>=4, Student’s <italic>t</italic>-test). (<bold>D</bold>) Immunoblot analyses of whole-cell lysates of EpH4-Snail cells treated with indicated concentration of simvastatin or 0.1% DMSO (‘0’ μM) in DMEM supplemented with 10% normal or lipid-free fetal bovine serum (FBS) for 48 h (<italic>n</italic>=3, Tukey–Kramer’s test). (<bold>E</bold>) Subcellular distribution of cholesterol stained with filipin. Scale bar, 10 μm. Intracellular signal to surface signal ratio was determined for three independent fields of view (Student’s <italic>t</italic>-test). (<bold>F</bold>) Live-cell images of lipid droplets (LDs) visualized by Lipi-Green dye. (<bold>G</bold>) Quantification of LD signal per cell. The Lipi-Green signals of all optical sections were summed and divided by the number of cells counted using DAPI images. Shown are means of three different fields of view ± SD. (<bold>H</bold>) Subcellular distribution of Topfluor-(TF-)cholesterol. Living cells were incubated with 5 μg/ml TF-cholesterol for 1 h, then stained with Lipi-Deepred and Nuc Blue. Scale bar, 20 μm. (<bold>I</bold>) Observation of filipin in EpH4-Snail cells expressing either EGFP-ADRP (LDs) or mRFP-LAMP1 (lysosome). Scale bar, 20 μm. (<bold>J</bold>) Comparison of cholesterol content relative to phospholipid (<italic>n</italic>=3, Student’s <italic>t</italic>-test). (<bold>K, L</bold>) Comparison of cell surface cholesterol (D4) and sphingomyelin (lysenin). Wild-type EpH4 cells expressing H2B-iRFP and EpH4-Snail cells were co-cultured and stained with recombinant lipid-binding proteins and CellMask Green (<bold>K</bold>). Quantification of fluorescent signals of lipid binding probes (<bold>L</bold>). Signal intensities per cell, relative to those of wild-type cells, were quantified and analyzed (<italic>n</italic> = 9 (D4) or 3 (lysenin), Student’s <italic>t</italic>-test). (<bold>M–O</bold>) Observation of lipid order of plasma membrane using FπCM-SO<sub>3</sub>. See also <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>. Wild-type EpH4 cells expressing H2B-iRFP and EpH4-Snail cells were co-cultured and stained with 1 μM FπCM-SO<sub>3</sub> for 10 min. The hue (red/blue ratio)–brightness (intensity) images of FπCM-SO<sub>3</sub> are shown with the confocal image of H2B-iRFP (magenta) (<bold>M</bold>). Scale bar, 20 μm. Normalized histogram of red/blue ratio values within FπCM-SO<sub>3</sub>-positive pixels (<bold>N</bold>). Comparison of mean red/blue ratio values (<bold>O</bold>) (<italic>n</italic>=3, Student’s <italic>t</italic>-test).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original raw data for the immunoblot images shown in <xref ref-type="fig" rid="fig2">Figure 2B and D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>, and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-104374-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Labeled full blot images for the immunoblot images shown in <xref ref-type="fig" rid="fig2">Figure 2B and D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>, and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-104374-fig2-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Contribution of transcription factors involved in ABCA1 transcription in epithelial cells.</title><p>(<bold>A</bold>) Immunoblot analysis of whole-cell lysates of EpH4-Snail (without treatment) and EpH4 cells treated with inhibitors of PI3K-Akt pathway (5 μM GSK2334470: PDK1, 50 μM LY294002: PI3K, or 1 μM Wortmannin: PI3K for 24 h). Comparison of protein levels of ABCA1 and phospho-FoxO3a is also shown (<italic>n</italic>=3, Tukey–Kramer’s test). (<bold>B</bold>) Immunoblot analysis of whole-cell lysates of EpH4 and EpH4-Snail cells (<italic>n</italic>=3, Student’s <italic>t</italic>-test). Quantitative analysis of c-myc expression is also shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Effect of ABCA1 knockout on nitidine chloride resistance of EpH4-Snail cells.</title><p>(<bold>A</bold>) Immunoblot analysis of whole-cell lysates of wild-type and two lines of ABCA1 KO EpH4-Snail cells (#1 and #2). (<bold>B</bold>) Effect of ABCA1 knockout on growth inhibitory effect of nitidine chloride. Cells were grown with or without 20 μM NC for 24 h, and cell number was determined with CCK-8. Fold change in cell number by NC was shown as relative to controls without NC (<italic>n</italic>=3, Tukey–Kramer’s test).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Visualization and analyses of lipid order using FπCM-SO<bold><sub>3</sub></bold>.</title><p>(<bold>A</bold>) Schematic illustrating the alteration of fluorescence spectra of solvatochromic dyes in lipid bilayers with different lipid compositions. A high content of sphingolipids and cholesterol induces an ordered acyl chain orientation. The dyes exhibit red-shifted fluorescence in disordered membranes and blue-shifted fluorescence in ordered membranes. (<bold>B</bold>) Schematic showing lipid-order visualization and analysis using FπCM-SO<sub>3</sub>. Living cells cultured on glass-bottom dishes were stained with 1 μM FπCM-SO<sub>3</sub> for 10 min. The dye was excited with a 405 nm laser, and emission signals of 400–500 nm (blue) and 500–700 nm (red) were separated using a variable dichroic mirror and simultaneously detected by two photomultipliers. The raw images were Gaussian-blurred, red/blue ratio and mean intensity of both channels were calculated. For visualization of lipid order, a ratio-intensity image was generated in which the hue represents the red/blue ratio and the brightness corresponds to the signal intensity (bottom left). For quantitative comparison, a threshold was set based on the fluorescence intensity of FπCM-SO<sub>3</sub>, and histograms of the red/blue ratio were generated from positive pixels (bottom center). For statistical assessment, mean red/blue ratio values of positive pixels were obtained and compared (bottom right).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig2-figsupp3-v1.tif"/></fig></fig-group><p>Since transcriptional activity of LXRs is regulated by cellular cholesterol level, we examined whether ABCA1 is expressed in response to high cholesterol accumulation in the cells. Inhibition of cholesterol biosynthesis by simvastatin, an inhibitor of the rate-limiting enzyme of cholesterol biosynthesis 3-hydroxy-3-methylglutaryl-coenzyme A reductase, remarkably decreased ABCA1 expression in EpH4-Snail cells, but residual ABCA1 was still detected (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, normal fetal bovine serum (FBS)). In contrast, treatment with simvastatin in the medium supplemented with lipid-free FBS completely abolished ABCA1 expression (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, lipid-free FBS). Together with the finding that incubation in lipid-free FBS medium alone did not markedly decrease ABCA1 expression, these results suggest that cholesterol biosynthesis is the primary source of excess accumulation of cholesterol in EpH4-Snail cells, but cholesterol uptake from media also significantly contributes to the accumulation as a secondary source.</p><p>These findings imply dysregulation of cholesterol metabolism in EpH4-Snail. Filipin staining revealed that cholesterol was prominently accumulated in intracellular structures in EpH4-Snail cells, whereas it localized primarily in the plasma membrane of wild-type EpH4 cells (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Since excess cholesterol can be stored in lipid droplets, we stained cells with Lipi-Green to visualize lipid droplets and found that lipid droplets were significantly enlarged in EpH4-Snail (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>). Consistently, TopFluor cholesterol, a fluorescent cholesterol analogue, was localized to lipid droplets in EpH4-Snail cells (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). On the other hand, the intracellular filipin signals did not co-localize with the lipid droplet protein ADRP (perilipin-2) but co-localized with the lysosomal protein LAMP1 instead (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). Given that filipin stains unesterified cholesterol, internalized cholesterol accumulates in lysosomes in its unesterified form and in lipid droplets in its esterified form in EpH4-Snail cells.</p><p>We next compared the total cholesterol levels in EpH4 cells and EpH4-Snail cells; the cellular amount of cholesterol slightly increased in EpH4-Snail cells, but the difference was modest and not significant (<xref ref-type="fig" rid="fig2">Figure 2J</xref>). Therefore, the internalization of cholesterol in EpH4-Snail cells is not simply due to an increase in the amount of cholesterol, but would be due to an abnormality in the subcellular distribution of cholesterol. A large proportion (30–50%) of cellular cholesterol is associated with sphingomyelin, and depletion of sphingomyelin induces internalization of cholesterol (<xref ref-type="bibr" rid="bib8">Das et al., 2014</xref>). To investigate contents of cholesterol and sphingomyelin in the plasma membrane, we utilized the lipid-binding protein probes domain 4 of perfringolysin O (cholesterol, D4) and lysenin (sphingomyelin). Intriguingly, cholesterol content in the plasma membrane was not affected by EMT, but sphingomyelin content decreased in EpH4-Snail cells (<xref ref-type="fig" rid="fig2">Figure 2K and L</xref>). Collectively, the increase in a sphingomyelin-unbound form of cholesterol in the plasma membrane results in the internalization of cholesterol and activation of LXR to induce ABCA1 expression in hybrid E/M cells.</p><p>The strong interaction between sphingolipids and cholesterol contributes to the formation of tightly packed and less fluid plasma membrane (<xref ref-type="bibr" rid="bib38">van Meer et al., 2008</xref>). Alteration of this physical property of plasma membrane frequently occurs in cancer cells and is thought to affect malignancy (<xref ref-type="bibr" rid="bib36">Szlasa et al., 2020</xref>). Therefore, we next addressed the impact of sphingomyelin decrease on the lipid packing of plasma membrane using FπCM-SO<sub>3</sub>, a recently developed plasma membrane-specific solvatochromic probe (<xref ref-type="bibr" rid="bib37">Tanaka et al., 2024</xref>). Solvatochromic dyes respond to the polarity of their environment, exhibiting a red shift in more polar solvents. In lipid bilayers, these dyes similarly sense differences in lipid packing (order) and display a red shift in more fluid, disordered membranes (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>). Thus, variations in lipid order can be visualized as changes in the ratio of signal intensities of the red to blue channels (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref>). The negatively charged and alkylated modifications enable FπCM-SO<sub>3</sub> to stably reside in the plasma membrane of living cells. Ratiometric imaging using FπCM-SO<sub>3</sub> revealed that the plasma membrane of EpH4-Snail cells was more disordered (<xref ref-type="fig" rid="fig2">Figure 2M–O</xref>). While plasma membrane fluidity is usually attributed to the cholesterol content (<xref ref-type="bibr" rid="bib35">Subczynski et al., 2017</xref>), our results suggest that ectopic expression of Snail induces fluidization of plasma membrane, not by altering the surface cholesterol level but by decreasing sphingomyelin content.</p></sec><sec id="s2-3"><title>Downregulation of VLCFA-SM synthesis induces Chol/SM imbalance in hybrid E/M cells</title><p>The present findings suggest that the cause of chemoresistance may trace back to alterations of the balance of sphingomyelin and cholesterol. Therefore, we next investigate how sphingomyelin metabolism is affected by ectopic expression of Snail. We found that the total sphingomyelin content relative to total phospholipids decreased in EpH4-Snail cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Consequently, the ratio of cholesterol to SM (Chol/SM ratio) in the cells significantly increased in EpH4-Snail cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). To investigate the SM profile in detail, we next analyzed the fatty acid composition of SM using LC-MS. In EpH4-Snail cells, the fractions of VLCFA-SMs (22:1, 22:0, and 24:1) were significantly decreased whereas those of LCFA-SMs (14:0, 16:1, and 16:0) were rather increased (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), resulting in a prominent decrease in the total VLCFA-SM fraction (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These results suggest that a decrease in VLCFA-SMs is responsible for a decrease in total SM content in EpH4-Snail cells. On the other hand, the decrease in the cell surface content (<xref ref-type="fig" rid="fig2">Figure 2L</xref>) was more prominent than that in total SM (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Given that VLCFA-SMs are suggested to be differently trafficked in recycling from endosome to plasma membrane (<xref ref-type="bibr" rid="bib19">Koivusalo et al., 2007</xref>), their reduction may lead to decreased plasma membrane sphingomyelin content by altering its intracellular distribution.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Effects of Snail-induced epithelial–mesenchymal transition (EMT) on sphingomyelin profile.</title><p>(<bold>A</bold>) Comparison of sphingomyelin (SM) content relative to phospholipid content (<italic>n</italic>=3, Student’s <italic>t</italic>-test). (<bold>B</bold>) Comparison of cholesterol (Chol)/SM ratio between EpH4 and EpH4-Snail cells (<italic>n</italic>=3, Student’s <italic>t</italic>-test). (<bold>C</bold>) Fatty acid composition of SM determined using LC-MS. All peaks corresponding to d18:1-even fatty acid-SMs were included in the analysis and each peak value is expressed as a percentage. n.d., peak not detected (<italic>n</italic>=3, Student’s <italic>t</italic>-test). (<bold>D</bold>) Pie charts of SM chain length profile from (C). SMs were classified into long-chain fatty acid (LCFA, orange) (≤20) and very long-chain fatty acid (VLCFA, purple) (&gt;20) SMs. (<bold>E</bold>) Chain length specificity of Elovls and CerSs responsible for fatty acid profile of sphingolipids reported (<xref ref-type="bibr" rid="bib22">Levy and Futerman, 2010</xref>; <xref ref-type="bibr" rid="bib30">Sassa and Kihara, 2014</xref>). Elovls catalyze a rate-limiting step of fatty acid elongation cycle, and CerSs catalyze <italic>N-</italic>acylation of sphingoid bases to produce ceramides. (<bold>F</bold>) Comparison of transcription levels of <italic>Elovl</italic>s and <italic>CerS</italic>s. Notable decreases in expressions of <italic>Elovl7</italic> and <italic>CerS3</italic> in EpH4-Snail cells are indicated by asterisks. (<bold>G</bold>) Quantification of transcription levels of <italic>Elovl7</italic> and <italic>CerS3</italic> relative to that of <italic>ZO-1</italic>, whose expression does not change between EpH4 and EpH4-Snail (<xref ref-type="bibr" rid="bib16">Ikenouchi et al., 2003</xref>) (<italic>n</italic>=3, Student’s <italic>t</italic>-test). (<bold>H</bold>) Effect of supplementation of C22:0 ceramide (Cer22:0) on ABCA1 expression. EpH4-Snail cells were treated with 10 μM ceramide or 0.4% vehicle (dodecane/ethanol = 2/98) for 24 h, then whole-cell lysates were analyzed by immunoblot (<italic>n</italic>=3, Student’s <italic>t</italic>-test). (<bold>I</bold>) Immunoblot analyses of whole-cell lysates of mouse epithelial (MTD-1A, CSG) and fibroblast (L-929, NIH3T3) cells. (<bold>J</bold>) Comparison of Chol/SM ratio of EpH4, EpH4-Snail, and normal fibroblasts (<italic>n</italic>=3, Dunnett’s test). (<bold>K</bold>) Comparison of Chol/SM ratio between TE-15 and TE-8 (<italic>n</italic>=3, Student’s <italic>t</italic>-test). (<bold>L</bold>) Scatter plot of Chol content against SM content used in (B), (H), and (I). Dashed lines indicate Chol/SM = 1.0 (blue) and 1.5 (red). The region of Chol/SM &gt;1.5 is shown with red background. (<bold>M</bold>) Possible mechanism of induction of ABCA1 expression and lipid droplet enlargement through decrease in VLCFA-SM. In EpH4 (epithelial) cells, a certain amount of cholesterol is sequestered through interaction with SM, organizing ordered plasma membrane (PM). In EpH4-Snail (hybrid E/M) cells, the lower level of VLCFA-SM biosynthesis leads to a decrease in plasma membrane SM content, resulting in membrane disorder. The increase in SM-unbound form of cholesterol in PM induces its internalization and activation of cellular cholesterol sensors, resulting in lipid droplet enlargement and enhanced ABCA1 expression.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original raw data for the RT-PCR and immunoblot images shown in <xref ref-type="fig" rid="fig3">Figure 3F, H and I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-104374-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Labeled uncropped gel and full blot images for the RT-PCR and immunoblot images shown in <xref ref-type="fig" rid="fig3">Figure 3F, H and I</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-104374-fig3-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Comparison of SM and cholesterol content.</title><p>(<bold>A, B</bold>) Comparison among EpH4, EpH4-Snail, and fibroblasts. (<bold>C, D</bold>) Comparison between esophageal cancer cell lines TE-15 (Snail-negative) and TE-8 (Snail-positive). n=3, **p&lt;0.01, *p&lt;0.05, n.s., p≥0.05 by Tukey’s multiple comparison test (<bold>A, B</bold>) and Student’s <italic>t</italic>-test (<bold>C, D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Fatty acid composition of SM is mainly modulated by substrate specificity of two families of enzymes, Elovls and CerSs, which respectively catalyze the rate-limiting step of the fatty acid elongation cycle and the N-acylation of sphingoid bases to produce ceramides (<xref ref-type="fig" rid="fig3">Figure 3E</xref>; <xref ref-type="bibr" rid="bib22">Levy and Futerman, 2010</xref>; <xref ref-type="bibr" rid="bib30">Sassa and Kihara, 2014</xref>). Therefore, we hypothesized that transcriptional repression of genes from these families causes the decrease in VLCFA-SM content in EpH4-Snail cells. RT-PCR analyses identified <italic>Elovl7</italic> and <italic>CerS3</italic> as genes that are repressed specifically in EpH4-Snail cells (<xref ref-type="fig" rid="fig3">Figure 3F and G</xref>). Consistent with our hypothesis, Elovl7 and CerS3 control VLCFA-SM production (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Collectively, ectopic expression of Snail represses transcription of VLCFA-SM-producing enzymes and results in a decrease in the amount of VLCFA-SM. This downregulation of biosynthesis pathway is responsible for the induction of ABCA1 expression because supplementation of VLCFA ceramide decreased the ABCA1 expression in EpH4-Snail cells (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Together with the results of the cholesterol depletion experiment (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), the high Chol/SM ratio due to downregulation of VLCFA-SM biosynthesis accounts for the elevated ABCA1 expression in EpH4-Snail cells.</p><p>Since ABCA1 expression is not aligned with either the loss of epithelial state (E-cadherin and α-catenin KO; <xref ref-type="fig" rid="fig1">Figure 1L</xref>) or a nonepithelial basal state (fibroblasts), upregulation of ABCA1 is characteristic to the hybrid E/M cells expressing ectopic Snail (<xref ref-type="fig" rid="fig3">Figure 3I</xref>). To investigate the mechanism underlying this difference in ABCA1 expression, we again compared Chol/SM ratio in EpH4-Snail and normal fibroblast cell lines L-929 and NIH3T3. Chol/SM ratio of these fibroblasts was slightly but not significantly higher than that of EpH4 (<xref ref-type="fig" rid="fig3">Figure 3J</xref>). The cholesterol content in NIH-3T3 cells is significantly higher than in EpH4 cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Consequently, normal fibroblasts would synthesize more SMs to counteract the cholesterol load imposed by the decrease in VLCFA-SMs and stabilize the Chol/SM ratio. By contrast, hybrid E/M cells are unable to respond appropriately to the harmful imbalance between cholesterol and SM due to the incomplete activation of the mesenchymal transcriptome.</p><p>To examine whether the above findings apply to human cancer cells, we investigate the Chol/SM ratio of TE-15 and TE-8 (see also <xref ref-type="fig" rid="fig1">Figure 1O</xref>; <xref ref-type="bibr" rid="bib26">Nishihira et al., 1993</xref>). Consistent with our findings in the EpH4-Snail system, Chol/SM ratio was significantly higher in TE-8 cells than in TE-15 cells (<xref ref-type="fig" rid="fig3">Figure 3K</xref>). Together with the results of mouse cell lines, normal epithelial and fibroblast cells maintain Chol/SM ratio around 1.0–1.5, and ABCA1 expression as a response to the excess Chol is induced when Chol/SM ratio exceeds 1.5 (<xref ref-type="fig" rid="fig3">Figure 3L</xref>). Notably, the difference in either cholesterol or SM contents between TE-15 and TE-8 cells, and cholesterol content between EpH4 and EpH4-Snail is not significant when each is compared alone (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), indicating the importance of considering their functional cooperativity, that is, to analyze the Chol/SM ratio. Collectively, the cause of chemoresistance can be traced back to the downregulation of VLCFA-SM biosynthesis (<xref ref-type="fig" rid="fig3">Figure 3M</xref>). A decrease in sphingomyelin but not in cholesterol induces plasma membrane fluidization, which leads to internalization of cholesterol. The internalized, SM-unbound cholesterol activates LXRs, which in turn elevate ABCA1 expression and thereby confer chemoresistance to cells.</p></sec><sec id="s2-4"><title>Inhibitor of cholesterol esterification selectively inhibits growth of Snail-positive kidney cancer cells</title><p>Finally, we examined the possibility of targeting the imbalance of Chol/SM ratio in Snail-positive cancer cells to selectively inhibit their growth. As discussed above, hybrid E/M cells of high Chol/SM ratio must either export cholesterol out of cells or isolate it within cells in lipid droplets as cholesteryl esters to avoid the cytotoxic effects of free cholesterol. Thus, inhibiting the means of clearing excess cholesterol could specifically target cells in the hybrid E/M state for self-extermination. Cholesterol efflux from cells is mainly dependent on ABCA1, and esterification of cholesterol is catalyzed by acyl-CoA:cholesterol acyl transferases (ACATs) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; <xref ref-type="bibr" rid="bib34">Song et al., 2021</xref>). Among the two ACAT isoforms in humans, SOAT1 is widely expressed, including in the kidney (<xref ref-type="bibr" rid="bib21">Lee et al., 1998</xref>). Indeed, all RCC cell lines tested expressed SOAT1 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), although the expression levels did not correlate with those of Snail in the respective cell lines (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Therefore, we examined the effect of ABCA1 inhibitor CsA and ACAT inhibitor TMP-153 on the EpH4-Snail model and renal carcinoma cells. While CsA non-selectively inhibited growth of all cell lines tested (<xref ref-type="fig" rid="fig4">Figure 4C and E</xref>), TMP-153 selectively inhibited growth of Snail-positive cells (EpH4-Snail, 786-O, A498, and Caki-1; <xref ref-type="fig" rid="fig4">Figure 4D and F</xref>). Thus, sequestration of cholesterol via esterification by ACATs is the primary mechanism for handling excess cholesterol to avoid cell death in these cells. Notably, TMP-153 treatment alone did not provide this selectivity between esophageal cancer cell lines, but the combination of TMP-153 and CsA selectively inhibited growth of the Snail-positive TE-8 cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–C</xref>). Collectively, these results suggest that inhibition of cholesterol efflux and cholesterol esterification selectively inhibits growth of cells stably in a Snail-induced hybrid E/M state.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Selective growth inhibition of Snail-positive cells by an ACAT inhibitor TMP-153.</title><p>(<bold>A</bold>) Schematic illustrating the molecular mechanisms for handling excess cholesterol to avoid cell death. Cells eliminate excess cholesterol through efflux mediated by transporters including ABCA1 or isolation into lipid droplets (LD) via esterification of cholesterol by acyl-CoA: cholesterol acyltransferases (ACATs) to avoid cell death. CsA and TMP-153 inhibit ABCA1 and ACATs, respectively. (<bold>B</bold>) Immunoblot analysis of whole-cell lysates of human kidney cell lines. Quantitative analysis of SOAT1 expression is also shown. (<bold>C–F</bold>), Effects of treatments with CsA (<bold>C</bold>, <bold>E</bold>) or TMP-153 (<bold>D</bold>, <bold>F</bold>) to cellular growth of EpH4 and EpH4-Snail (<bold>C</bold>, <bold>D</bold>) or human kidney cancer cell lines (<bold>E</bold>, <bold>F</bold>). Cells were treated with drugs for 24 h and relative cell number to 0.1% DMSO control was determined by CCK-8. Results are shown as mean of at least three independent experiments ± SD. (<bold>G–I</bold>) TMP-153 inhibits the growth of tumor xenografts composed of Snail-positive renal cancer 786-O cells. Experiments were performed as described in ‘Materials and methods’. In brief, 50 mg/kg TMP-153 was administered intraperitoneally to nude mice bearing 786-O tumor xenografts. After 21 days of the first administration, the overall appearance (<bold>G</bold>) and the excised tumors (<bold>H</bold>) of control and treated mice were compared. (<bold>I</bold>) Tumor growth curve in the xenograft model. Results are shown as mean of four biological replicates ± SD (Student’s <italic>t-</italic>test).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original raw data for the immunoblot images shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-104374-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Labeled full blot images for the immunoblot images shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-104374-fig4-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Selective growth inhibition of a Snail positive esophageal cancer cell line by combined treatment of CsA and TMP-153.</title><p>(<bold>A–C</bold>) Effects of treatments with CsA (<bold>A</bold>), TMP-153 (<bold>B</bold>), or combination of 50 μM CsA and indicated concentration of TMP-153 (<bold>C</bold>) to cellular growth of human esophageal cancer cell lines TE-15 and TE-8. Cells were treated with drugs for 24 h and relative cell number to 0.1% DMSO control was determined by CCK-8. n≥3, error bars, SDs (one-sided Student’s <italic>t</italic>-test). (<bold>D–F</bold>) Combined treatment of CsA and TMP-153 inhibits the growth of TE-8 tumor xenografts. Experiments were performed as described in ‘Materials and methods’. In brief, 10 mg/kg CsA and 10 mg/kg TMP-153 were simultaneously administered intraperitoneally to nude mice bearing TE-8 tumor xenografts. After 36 days of the first administration, the overall appearance (<bold>D</bold>), the excised tumors (<bold>E</bold>), and the tumor size (<bold>F</bold>) of control and treated mice were compared. n=5, error bars, SDs (Student’s <italic>t-</italic>test).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104374-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We also investigated the potential of ACAT inhibitors as anti-tumor agents in vivo using xenograft models. We successfully transplanted the 786-O line into nude mice among Snail-positive ccRCC cell lines. Using this system, we found that TMP-153 treatment significantly reduced 786-O tumor volume in vivo (<xref ref-type="fig" rid="fig4">Figure 4G–I</xref>). Moreover, the combination of TMP-153 and CsA also inhibited the growth of TE-8 tumor xenografts (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D–F</xref>). Together with the in vitro assays (<xref ref-type="fig" rid="fig4">Figure 4C–F</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–C</xref>), we propose that cholesterol clearance systems, particularly ACATs, can be used as molecular targets to selectively inhibit the growth of Snail-positive cancers.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In recent years, it has been revealed that the expression of EMT-TFs, such as Snail, induces cancer cells to acquire mesenchymal characteristics while retaining epithelial traits, transforming them into so-called hybrid E/M cells. Hybrid E/M cells have been demonstrated to exhibit the highest plasticity and malignancy (<xref ref-type="bibr" rid="bib1">Aiello et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Pastushenko et al., 2018</xref>). Moreover, Snail expression contributes to cancer stemness and resistance to chemotherapy (<xref ref-type="bibr" rid="bib20">Lambert and Weinberg, 2021</xref>). To date, molecular mechanisms connecting to EMT-TFs to chemoresistance remain to be established. Here, we identify lipid metabolic imbalance-mediated ABCA1 expression as a mechanism of chemoresistance induced by Snail. We found reduced VLCFA-SM biosynthesis in Snail-positive cells with hybrid E/M phenotypes, resulting in high Chol/SM ratio. This should be detrimental in theory since it increases exposure to the toxic effect of free cholesterol, but cancer cells deploy countermeasures: upregulating ABCA1 to move cholesterol out of cells and sequestering esterified cholesterol in the form of lipid droplets. Notably, it has been also reported that not only ABCA1 (<xref ref-type="bibr" rid="bib18">Iwasaki et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Wang et al., 2021</xref>) but also enhanced lipid droplet formation triggers chemoresistance to various drugs (<xref ref-type="bibr" rid="bib31">Schlaepfer et al., 2012</xref>; <xref ref-type="bibr" rid="bib5">Cotte et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Hultsch et al., 2018</xref>). Therefore, dietary or pharmacological control of cholesterol and also sphingolipids would be a new strategy to overcome resistance to chemotherapy.</p><p>The aberrant activation of EMT-TFs is implicated in multiple crucial steps in cancer progression, prompting efforts to explore therapeutic approaches aimed at suppressing EMT-TF functions in cancer cells (<xref ref-type="bibr" rid="bib9">Davis et al., 2014</xref>). However, as EMT-TFs are predominantly located in the nucleus, no effective treatment methods, including antibody drugs, have been established thus far. Therefore, instead of directly targeting EMT-TFs, focusing on the metabolic network vulnerabilities specific to hybrid E/M cells may prove to be an effective therapeutic strategy. In the present study, we found increased sensitivity of Snail-positive cells to toxicity of free-cholesterol accumulation induced by the ACAT inhibitor TMP-153. Notably, kidney cancer growth could be suppressed by inhibiting cholesterol esterification alone, while esophageal cancer required the additional downregulation of ABCA1, indicating varying dependence on free cholesterol clearance strategies among cancers of different primary origin. Other cancers might employ alternative pathways to evade cytotoxic effects of excess cholesterol, and identifying these traits will pave the way for the development of novel strategies in targeted molecular therapeutics against hybrid E/M cancers. An intriguing corollary here is the potential utility of ABCA1 expression as a diagnostic marker to identify cancers that would be sensitive to targeting the Chol/SM imbalance.</p><p>Although various metabolic changes in cancer cells focusing on energy sources including sugars, amino acids, and fatty acids have been intensely studied (<xref ref-type="bibr" rid="bib29">Pavlova et al., 2022</xref>), alteration of sphingolipid homeostasis driven by EMT-TFs remains largely unknown. We found both quantitative and qualitative alteration of sphingomyelin profile: decrease in the total SM amount and the VLCFA-SM percentage. This alteration is attributed to transcriptional repression of enzymes for biosynthesis of VLCFA-SMs, CerS3, and Elovl7. Genes whose transcription is repressed by Snail include those encoding proteins directly involved in epithelial adhesive structures, such as E-cadherin and Claudins. Hence, it is not surprising that VLCFA-SMs play important roles cooperatively with the adhesion molecules. Indeed, cholesterol accumulation is required for tight junction formation, and VLCFA-SMs are enriched in the junctional region (<xref ref-type="bibr" rid="bib32">Shigetomi et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Shigetomi et al., 2023</xref>). Studies focusing on the VLCFA-synthetic enzymes would provide a new layer of knowledge about mechanisms underlying the establishment of epithelial structures and functions. Such studies would also contribute to understanding how dysfunctions in lipid metabolism promote cancer malignancy and tissue fibrosis as a consequence of EMT. The regulation of cell adhesion by fine-tuning of lipid composition should be reversible and therefore would explain the two conflicting events: the invasion and metastasis process and the viability process at the metastatic site.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cells and reagents</title><p>Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS under 5% CO<sub>2</sub> at 37°C. Mouse Snail-expressing EpH4 cells (EpH4-Snail) (<xref ref-type="bibr" rid="bib16">Ikenouchi et al., 2003</xref>), E-cadherin KO and α-catenin KO EpH4 cells (<xref ref-type="bibr" rid="bib32">Shigetomi et al., 2018</xref>) were generated previously. EpH4-Snail cells were maintained in medium supplemented with 500 μg/ml G418 (Wako Pure Chemical). EpH4 cells were kindly provided by Dr. Reichmann (Institut Suisse de Recherches, Lausanne, Switzerland), and amplification of mouse-specific genomic sequences was confirmed. HEK293, 786-O, and A498 cells were obtained from the American Type Culture Collection (ATCC); Caki-1 and KMRC-3 cells were obtained from the Japanese Collection of Research Bioresources Cell Bank; TE-8 and TE-15 cells were obtained from the Tohoku University Cell Resource Center for Biomedical Research; and TUHR14TKB cells were obtained from the RIKEN BioResource Research Center. Human cell lines were authenticated by short tandem repeat profiling using the GenePrint10 System (Promega). All cell lines were routinely tested and confirmed to be negative for mycoplasma contamination.</p><p>pLVET-HA-K-RasG12V-IRES-GFP (Addgene #107140), LAMP1-mRFP-FLAG (#34611), and pLentiPGK DEST H2B-iRFP670 (#90237) were transduced using the lentivirus produced in HEK293 cells, and fluorescence-positive cells were collected using a cell sorter Sony SH-800 as needed. pEGFP-C1-ADRP (Addgene #78161) was transfected to cells using Lipofectamine 3000 (Thermo Fisher). Nitidine chloride was purchased from Selleck Biotech, cyclosporin A from Wako, and TMP-153 from Cayman Chemical, filipin complex from <italic>Streptomyces filipinensis</italic> and GSK2033 from Sigma-Aldrich, Lipi-Green from Dojindo Laboratories, and ceramide (d18:1/22:0; C22:0 ceramide) from Avanti Polar Lipids.</p><p>The following primary antibodies were used for immunoblotting (IB), immunofluorescence microscopy (IF), and immunohistochemistry (IHC): rabbit anti-ABCA1 mAb (96292S, IB, IF), rabbit anti-Snail mAb (3879S, IB), rabbit anti-Akt mAb (4691S, IB), rabbit anti-phospho-Akt (T308) mAb (2965S, IB), and rabbit anti-phospho-FoxO3a (S253) pAb (9466S, IB) from Cell Signaling Technology; rabbit anti-ABCA1 pAb (NB400-105, IHC) from Novus Biologicals; rat anti-E-cadherin mAb (ECCD-2, IB, IF) from TaKaRa; mouse anti-cytokeratin 18 mAb (LS-C84878, IF) from LS Bio; goat anti-LXR alpha + LXR beta pAb (ab24362, IF) from Abcam; and mouse anti-α-tubulin mAb (12G10, IB) produced in house.</p><p>The following secondary antibodies were used: Horseradish Peroxidase (HRP)-conjugated anti-rat IgG (HAF005) and anti-mouse IgG (HAF007) from R&amp;D Systems; HRP-conjugated anti-rabbit IgG (4030-05) from Southern Biotech; and Cy3-conjugated anti-goat IgG (705-165-147) from Jackson Immunoresearch Laboratories.</p></sec><sec id="s4-2"><title>RT-PCR</title><p>Total RNAs were prepared with RNeasy Mini Kit (QIAGEN) and the retrotranscribed with Superscript III First-Strand Synthesis System (Invitrogen). RT-PCR was then performed using KOD FX (TOYOBO) following manufacturer’s instructions. Primer sequences used are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-3"><title>Lipid analysis</title><p>Total lipids were extracted from cultured cells by Bligh–Dyer’s method, dissolved in methanol/chloroform = 1/1 (v/v). Phospholipid content was determined by phosphate assay. SM and Chol content were determined using Sphingomyelin assay kit STA-601 (Cell Biolabs) and Amplex Red Cholesterol Assay Kit (Invitrogen), respectively, according to the manufacturer’s instructions. Fatty acid profile of SM was determined with LC-MS as described previously (<xref ref-type="bibr" rid="bib17">Ikenouchi et al., 2012</xref>). Briefly, electrospray ionization mass spectrometry analysis was performed on a 6420 triple-quadrupole liquid chromatography–mass spectrometer (Agilent Technologies) equipped with an HPLC system and an auto sampler (Infinity 1260; Agilent Technologies). The extracted lipids were directly subjected to electrospray ionization mass spectrometry analysis. The mobile phase composition was acetonitrile/methanol/water = 18:11:1 (0.1% ammonium formate). The flow rate was 4 μl/min. The mass range of the instrument was set at 650–950 <italic>m/z. m/z</italic> profiles of SM were extracted according to total ion chromatogram patterns, and all peaks corresponding to [M+H]<sup>+</sup> ions of d18:1-even chain length fatty acid-SMs were subjected to analyses.</p></sec><sec id="s4-4"><title>Fluorescence microscopy</title><p>To visualize subcellular localization of cholesterol, cells cultured on glass-bottom dishes were fixed with 4% paraformaldehyde for 15 min at room temperature (RT) and stained with 50 μg/ml filipin prepared in Phosphate-Buffered Saline (PBS) for 30 min. To visualize lipid droplets, live cells were washed once with Hank’s Balanced Salt Solution (HBSS) and stained with Lipi-Green (Dojindo) for 20 min at 37°C. Cells were washed twice with HBSS and observed on a heating stage at 37°C. For immunofluorescence microscopy, cells cultured on coverslips were fixed with 4% paraformaldehyde or 2% formalin prepared in PBS for 15 min at RT and permeabilized with 0.1% Triton X-100 prepared in PBS. Fixed cells were blocked with 1% BSA prepared in PBS for 1 h at RT. Cells were incubated with primary antibodies for 1 h at RT and secondary antibodies for 1 h at RT. Antibodies were prepared in the blocking solution. For detection of ABCA1, cells were fixed with MeOH for 20 min at –30°C and antibodies were prepared in Can Get Signal immunostain Immunoreaction Enhancer Solution B (TOYOBO). Fixed cells were observed at RT. For imaging of plasma membrane cholesterol and sphingomyelin, cells cultured on glass-bottom dishes were washed with HBSS three times, incubated with 1x working solution of CellMask Green plasma membrane stain (Molecular Probes) in HBSS, subsequently incubated with 5 μg recombinant scarlet-tagged D4 or 10 μg RFP-tagged lysenin in 100 μl HBSS for 30 min, washed three times with HBSS, and observed at 37°C. For ratiometric imaging using FπCM-SO<sub>3</sub> (<xref ref-type="bibr" rid="bib37">Tanaka et al., 2024</xref>), cells cultured on glass-bottom dishes were incubated with 1 mM FπCM-SO<sub>3</sub> in HBSS for 10 min at 37°C and observed at 37°C without washout. The dye was excited with a 405 nm laser, and 400–500 nm (blue) and 500–700 nm (red) signals were split with variable dichroic mirror and simultaneously detected with two photomultipliers. The raw images were Gaussian blurred, ratio and mean intensity of two channels were calculated, and then data were expressed as a hue (ratio) – brightness (intensity) image (see <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). All observations were performed with a confocal microscope (Carl Zeiss LSM900) equipped with Plan-APO (63×/1.40 NA, oil immersion) objective. Images were acquired using Carl Zeiss Zen 3.4 software. Images were analyzed using ImageJ/Fiji.</p></sec><sec id="s4-5"><title>Immunoblotting</title><p>Whole cells were lysed with Sodium Dodecyl Sulfate (SDS) sample buffer and samples were resolved by SDS-PAGE and transferred to nitrocellulose membranes. After blocking with 5% skim milk prepared in TBS-T, membranes were incubated with primary antibody for 1 h at RT or overnight at 4°C. Membranes were then washed and incubated with HRP-conjugated secondary antibody for 1 h at RT. Chemiluminescence signal was detected using a LAS4000mini imaging system (Fujifilm), and images were analyzed using ImageJ/Fiji. Protein levels were calculated relative to the signal intensity of α-tubulin as a loading control.</p></sec><sec id="s4-6"><title>Ceramide supplementation to culture medium</title><p>C22:0 ceramide was supplemented to culture medium as described previously (<xref ref-type="bibr" rid="bib24">McNally et al., 2022</xref>). The ceramide was dissolved in dodecane/ethanol = 2/98 solution at 0.63 mM (stock solution). The stock solution (or vehicle control) was added to DMEM + 10% FBS medium at a final solvent concentration of 0.4%, resulting in a final ceramide concentration of 2.5 μM. The prepared medium was used immediately. Cells were cultured in this medium for 24 h and then subjected to further analysis.</p></sec><sec id="s4-7"><title>Growth inhibition assay</title><p>Cells cultured in 96-well microtiter plates (2×10<sup>3</sup> cells/well, 48 h) were subjected to treatments with nitidine chloride, GSK2033, CsA, TMP-153, or their combination dissolved in Dimethyl Sulfoxide (DMSO) for 24 h at 37°C. In experiments involving GSK2033, the compound was added 24 h prior to treatment with the other drugs. Final DMSO concentrations were less than 0.25%. After treatment, metabolically active cell number was determined using Cell Counting Kit-8 (Dojindo) according to the manufacturer’s instructions. Briefly, 10 μl of CCK-8 solution was directly added to each well containing 100 μl culture medium and cells were incubated 1 h at 37°C. Reaction was stopped by adding 10 μl of 1% sodium dodecyl sulfate prepared in MQ and plates were put at 4°C to avoid additional reaction. Absorbance of solution at 450 nm was measured using a spectrophotometer (Thermo GENESYS 10S UV-Vis). Data were expressed as relative to 0.25% DMSO control.</p></sec><sec id="s4-8"><title>Immunohistochemistry</title><p>Formalin-fixed and paraffin-embedded surgical specimens were cut into 3 μm sections. These sections were immersed in antigen retrieval solution (pH 9.0) (Nichirei Bioscience Inc) and heated in a pressure chamber. Then, the sections were incubated with the primary antibodies (rabbit anti-ABCA1 pAb, NB400-105) and later incubated with HRP-labeled goat anti-rabbit secondary antibodies (Nichirei Bioscience Inc). Immunoreactivity was visualized by using 3–3 Diaminobenzidine Dab Substrate Kits (Nichirei Bioscience Inc). Informed consent for experimental use of the samples was obtained from all patients in accordance with the ethical guidelines of Aichi Cancer Center, and the study was approved by the Institutional Review Board (approval no. 2021-0-037). DAB signals were extracted from RGB images by color deconvolution, inverted, and quantified as the mean intensity of pixels exceeding a defined threshold using ImageJ/Fiji.</p></sec><sec id="s4-9"><title>Tumor xenograft model</title><p>Four-week-old female athymic nude mice were purchased from Japan SLC and housed in a specific pathogen-free facility. All animal experiments were conducted in accordance with the Guidelines for Animal Experiments of Aichi Medical University and approved by the Institutional Animal Care and Use Committee (approval no. 2024-58).</p><p>To initiate xenografting of 786-O, 2 × 10<sup>6</sup> cells in 200  μl DMEM were subcutaneously injected into the back of mice by using a 27G needle. After 7 days, when the inoculated tumor became visible, the mice were randomly divided into treatment and control groups, and treatment was initiated (day 0). TMP-153 (50  mg/kg body weight) or vehicle (0.5% hydroxypropyl methylcellulose with 0.1% polysorbate 80) was intraperitoneally administered to each mouse on days 0, 4, 7, 11, 14, and 18 to each mouse. The tumor volume was measured every week and calculated using the modified ellipsoid formula (1/2 × length × width<sup>2</sup>). The xenografting of TE-8 was performed with some modifications. For this, 1 × 10<sup>7</sup> cells were injected. A combination of TMP-153 and CsA (both at 10  mg/kg body weight) or vehicle was intraperitoneally administered to each mouse on days 0 and 4. Finally, the tumor volume was measured 36 days after the first administration.</p></sec><sec id="s4-10"><title>Statistical analysis</title><p>Microsoft Excel for Microsoft 365 MSO 2306, GraphPad Prism v8.4.1, and Python version 3.12.7 were used for analyses and displays of quantitative data. Data are expressed as mean, with each point or error bars representing standard deviations (SD). Significant difference is indicated as follows: *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Resources, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Resources</p></fn><fn fn-type="con" id="con4"><p>Resources</p></fn><fn fn-type="con" id="con5"><p>Resources</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Informed consent for experimental use of the samples was obtained from all patients in accordance with the ethical guidelines of Aichi Cancer Center, and the study was approved by the Institutional Review Board (Approval No. 2021-0-037).</p></fn><fn fn-type="other"><p>All animal experiments were conducted in accordance with the Guidelines for Animal Experiments of Aichi Medical University and approved by the Institutional Animal Care and Use Committee (Approval No. 2024-58).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-104374-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Primer sequences used in this study.</title></caption><media xlink:href="elife-104374-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank all members of the Ikenouchi Laboratory for helpful discussions, Takana Motoyoshi (KI Stainer) for immunohistochemistry, Teruaki Fujishita and Masahiro Aoki for technical advice on xenograft experiments, Minako Suzuki for technical assistance, and Kenji Kasai for pathological advice. This work was supported by AMED-FORCE (21444781) (JI), JSPS KAKENHI (JP25H00994 [JI], JP25H01325 [JI], JP25K22454 [JI], JP22KJ2374 [AM], and JP25K18465 [AM]), JST-FOREST (JPMJFR204L) (JI), and Grants from Takeda Science Foundation (JI) and the Ono Medical Research Foundation (JI).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>NM</given-names></name><name><surname>Maddipati</surname><given-names>R</given-names></name><name><surname>Norgard</surname><given-names>RJ</given-names></name><name><surname>Balli</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Yamazoe</surname><given-names>T</given-names></name><name><surname>Black</surname><given-names>T</given-names></name><name><surname>Sahmoud</surname><given-names>A</given-names></name><name><surname>Furth</surname><given-names>EE</given-names></name><name><surname>Bar-Sagi</surname><given-names>D</given-names></name><name><surname>Stanger</surname><given-names>BZ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>EMT subtype influences epithelial plasticity and mode of cell migration</article-title><source>Developmental Cell</source><volume>45</volume><fpage>681</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2018.05.027</pub-id><pub-id pub-id-type="pmid">29920274</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arner</surname><given-names>EN</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Brekken</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Behind the wheel of epithelial plasticity in KRAS-Driven Cancers</article-title><source>Frontiers in Oncology</source><volume>9</volume><elocation-id>1049</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.01049</pub-id><pub-id pub-id-type="pmid">31681587</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batlle</surname><given-names>E</given-names></name><name><surname>Sancho</surname><given-names>E</given-names></name><name><surname>Francí</surname><given-names>C</given-names></name><name><surname>Domínguez</surname><given-names>D</given-names></name><name><surname>Monfar</surname><given-names>M</given-names></name><name><surname>Baulida</surname><given-names>J</given-names></name><name><surname>García De Herreros</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells</article-title><source>Nature Cell Biology</source><volume>2</volume><fpage>84</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/35000034</pub-id><pub-id pub-id-type="pmid">10655587</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cano</surname><given-names>A</given-names></name><name><surname>Pérez-Moreno</surname><given-names>MA</given-names></name><name><surname>Rodrigo</surname><given-names>I</given-names></name><name><surname>Locascio</surname><given-names>A</given-names></name><name><surname>Blanco</surname><given-names>MJ</given-names></name><name><surname>del Barrio</surname><given-names>MG</given-names></name><name><surname>Portillo</surname><given-names>F</given-names></name><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression</article-title><source>Nature Cell Biology</source><volume>2</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/35000025</pub-id><pub-id pub-id-type="pmid">10655586</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotte</surname><given-names>AK</given-names></name><name><surname>Aires</surname><given-names>V</given-names></name><name><surname>Fredon</surname><given-names>M</given-names></name><name><surname>Limagne</surname><given-names>E</given-names></name><name><surname>Derangère</surname><given-names>V</given-names></name><name><surname>Thibaudin</surname><given-names>M</given-names></name><name><surname>Humblin</surname><given-names>E</given-names></name><name><surname>Scagliarini</surname><given-names>A</given-names></name><name><surname>de Barros</surname><given-names>J-PP</given-names></name><name><surname>Hillon</surname><given-names>P</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Delmas</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>322</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02732-5</pub-id><pub-id pub-id-type="pmid">29358673</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cserepes</surname><given-names>J</given-names></name><name><surname>Szentpétery</surname><given-names>Z</given-names></name><name><surname>Seres</surname><given-names>L</given-names></name><name><surname>Ozvegy-Laczka</surname><given-names>C</given-names></name><name><surname>Langmann</surname><given-names>T</given-names></name><name><surname>Schmitz</surname><given-names>G</given-names></name><name><surname>Glavinas</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>I</given-names></name><name><surname>Homolya</surname><given-names>L</given-names></name><name><surname>Váradi</surname><given-names>A</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name><name><surname>Elkind</surname><given-names>NB</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization</article-title><source>Biochemical and Biophysical Research Communications</source><volume>320</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.06.037</pub-id><pub-id pub-id-type="pmid">15240127</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>ZP</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antitumor functions and mechanisms of nitidine chloride in human cancers</article-title><source>Journal of Cancer</source><volume>11</volume><fpage>1250</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.7150/jca.37890</pub-id><pub-id pub-id-type="pmid">31956371</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><name><surname>Anderson</surname><given-names>DD</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Radhakrishnan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis</article-title><source>eLife</source><volume>3</volume><elocation-id>e02882</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.02882</pub-id><pub-id pub-id-type="pmid">24920391</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>FM</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Thompson</surname><given-names>EW</given-names></name><name><surname>Monteith</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting EMT in cancer: opportunities for pharmacological intervention</article-title><source>Trends in Pharmacological Sciences</source><volume>35</volume><fpage>479</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.06.006</pub-id><pub-id pub-id-type="pmid">25042456</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debaugnies</surname><given-names>M</given-names></name><name><surname>Rodríguez-Acebes</surname><given-names>S</given-names></name><name><surname>Blondeau</surname><given-names>J</given-names></name><name><surname>Parent</surname><given-names>M-A</given-names></name><name><surname>Zocco</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>de Maertelaer</surname><given-names>V</given-names></name><name><surname>Moers</surname><given-names>V</given-names></name><name><surname>Latil</surname><given-names>M</given-names></name><name><surname>Dubois</surname><given-names>C</given-names></name><name><surname>Coulonval</surname><given-names>K</given-names></name><name><surname>Impens</surname><given-names>F</given-names></name><name><surname>Van Haver</surname><given-names>D</given-names></name><name><surname>Dufour</surname><given-names>S</given-names></name><name><surname>Uemura</surname><given-names>A</given-names></name><name><surname>Sotiropoulou</surname><given-names>PA</given-names></name><name><surname>Méndez</surname><given-names>J</given-names></name><name><surname>Blanpain</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>RHOJ controls EMT-associated resistance to chemotherapy</article-title><source>Nature</source><volume>616</volume><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05838-7</pub-id><pub-id pub-id-type="pmid">36949199</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Jiao</surname><given-names>W</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nitidine chloride induces apoptosis and inhibits tumor cell proliferation via suppressing ERK signaling pathway in renal cancer</article-title><source>Food and Chemical Toxicology</source><volume>66</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2014.01.049</pub-id><pub-id pub-id-type="pmid">24508476</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>KR</given-names></name><name><surname>Durrans</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>STC</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>El Rayes</surname><given-names>T</given-names></name><name><surname>Ryu</surname><given-names>S</given-names></name><name><surname>Troeger</surname><given-names>J</given-names></name><name><surname>Schwabe</surname><given-names>RF</given-names></name><name><surname>Vahdat</surname><given-names>LT</given-names></name><name><surname>Altorki</surname><given-names>NK</given-names></name><name><surname>Mittal</surname><given-names>V</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance</article-title><source>Nature</source><volume>527</volume><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/nature15748</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frechin</surname><given-names>M</given-names></name><name><surname>Stoeger</surname><given-names>T</given-names></name><name><surname>Daetwyler</surname><given-names>S</given-names></name><name><surname>Gehin</surname><given-names>C</given-names></name><name><surname>Battich</surname><given-names>N</given-names></name><name><surname>Damm</surname><given-names>E-M</given-names></name><name><surname>Stergiou</surname><given-names>L</given-names></name><name><surname>Riezman</surname><given-names>H</given-names></name><name><surname>Pelkmans</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell-intrinsic adaptation of lipid composition to local crowding drives social behaviour</article-title><source>Nature</source><volume>523</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/nature14429</pub-id><pub-id pub-id-type="pmid">26009010</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hultsch</surname><given-names>S</given-names></name><name><surname>Kankainen</surname><given-names>M</given-names></name><name><surname>Paavolainen</surname><given-names>L</given-names></name><name><surname>Kovanen</surname><given-names>R-M</given-names></name><name><surname>Ikonen</surname><given-names>E</given-names></name><name><surname>Kangaspeska</surname><given-names>S</given-names></name><name><surname>Pietiäinen</surname><given-names>V</given-names></name><name><surname>Kallioniemi</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Association of tamoxifen resistance and lipid reprogramming in breast cancer</article-title><source>BMC Cancer</source><volume>18</volume><elocation-id>850</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-018-4757-z</pub-id><pub-id pub-id-type="pmid">30143015</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatova</surname><given-names>ID</given-names></name><name><surname>Angdisen</surname><given-names>J</given-names></name><name><surname>Moran</surname><given-names>E</given-names></name><name><surname>Schulman</surname><given-names>IG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Differential regulation of gene expression by LXRs in response to macrophage cholesterol loading</article-title><source>Molecular Endocrinology</source><volume>27</volume><fpage>1036</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1210/me.2013-1051</pub-id><pub-id pub-id-type="pmid">23686114</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikenouchi</surname><given-names>J</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Furuse</surname><given-names>M</given-names></name><name><surname>Tsukita</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail</article-title><source>Journal of Cell Science</source><volume>116</volume><fpage>1959</fpage><lpage>1967</lpage><pub-id pub-id-type="doi">10.1242/jcs.00389</pub-id><pub-id pub-id-type="pmid">12668723</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikenouchi</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Umeda</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Taguchi</surname><given-names>R</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>SB</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Stolz</surname><given-names>DB</given-names></name><name><surname>Umeda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Lipid polarity is maintained in absence of tight junctions</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>9525</fpage><lpage>9533</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.327064</pub-id><pub-id pub-id-type="pmid">22294698</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>H</given-names></name><name><surname>Okabe</surname><given-names>T</given-names></name><name><surname>Takara</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Hanashiro</surname><given-names>K</given-names></name><name><surname>Oku</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of nitidine</article-title><source>Cancer Chemotherapy and Pharmacology</source><volume>66</volume><fpage>953</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1007/s00280-010-1247-7</pub-id><pub-id pub-id-type="pmid">20238115</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koivusalo</surname><given-names>M</given-names></name><name><surname>Jansen</surname><given-names>M</given-names></name><name><surname>Somerharju</surname><given-names>P</given-names></name><name><surname>Ikonen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Endocytic trafficking of sphingomyelin depends on its acyl chain length</article-title><source>Molecular Biology of the Cell</source><volume>18</volume><fpage>5113</fpage><lpage>5123</lpage><pub-id pub-id-type="doi">10.1091/mbc.e07-04-0330</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>AW</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Linking EMT programmes to normal and neoplastic epithelial stem cells</article-title><source>Nature Reviews. Cancer</source><volume>21</volume><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00332-6</pub-id><pub-id pub-id-type="pmid">33547455</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>O</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Chang</surname><given-names>TY</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Immunodepletion experiments suggest that acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines</article-title><source>Journal of Lipid Research</source><volume>39</volume><fpage>1722</fpage><lpage>1727</lpage><pub-id pub-id-type="pmid">9717734</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mammalian ceramide synthases</article-title><source>IUBMB Life</source><volume>62</volume><fpage>347</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1002/iub.319</pub-id><pub-id pub-id-type="pmid">20222015</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makhov</surname><given-names>P</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Ghatalia</surname><given-names>P</given-names></name><name><surname>Kutikov</surname><given-names>A</given-names></name><name><surname>Uzzo</surname><given-names>RG</given-names></name><name><surname>Kolenko</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies</article-title><source>Molecular Cancer Therapeutics</source><volume>17</volume><fpage>1355</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-1299</pub-id><pub-id pub-id-type="pmid">29967214</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNally</surname><given-names>BD</given-names></name><name><surname>Ashley</surname><given-names>DF</given-names></name><name><surname>Hänschke</surname><given-names>L</given-names></name><name><surname>Daou</surname><given-names>HN</given-names></name><name><surname>Watt</surname><given-names>NT</given-names></name><name><surname>Murfitt</surname><given-names>SA</given-names></name><name><surname>MacCannell</surname><given-names>ADV</given-names></name><name><surname>Whitehead</surname><given-names>A</given-names></name><name><surname>Bowen</surname><given-names>TS</given-names></name><name><surname>Sanders</surname><given-names>FWB</given-names></name><name><surname>Vacca</surname><given-names>M</given-names></name><name><surname>Witte</surname><given-names>KK</given-names></name><name><surname>Davies</surname><given-names>GR</given-names></name><name><surname>Bauer</surname><given-names>R</given-names></name><name><surname>Griffin</surname><given-names>JL</given-names></name><name><surname>Roberts</surname><given-names>LD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Long-chain ceramides are cell non-autonomous signals linking lipotoxicity to endoplasmic reticulum stress in skeletal muscle</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>1748</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-29363-9</pub-id><pub-id pub-id-type="pmid">35365625</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>MA</given-names></name><name><surname>Huang</surname><given-names>RYJ</given-names></name><name><surname>Jackson</surname><given-names>RA</given-names></name><name><surname>Thiery</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>EMT: 2016</article-title><source>Cell</source><volume>166</volume><fpage>21</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.028</pub-id><pub-id pub-id-type="pmid">27368099</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishihira</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Katayama</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Kuroki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Molecular and cellular features of esophageal cancer cells</article-title><source>Journal of Cancer Research and Clinical Oncology</source><volume>119</volume><fpage>441</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1007/BF01215923</pub-id><pub-id pub-id-type="pmid">8509434</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padmanaban</surname><given-names>V</given-names></name><name><surname>Krol</surname><given-names>I</given-names></name><name><surname>Suhail</surname><given-names>Y</given-names></name><name><surname>Szczerba</surname><given-names>BM</given-names></name><name><surname>Aceto</surname><given-names>N</given-names></name><name><surname>Bader</surname><given-names>JS</given-names></name><name><surname>Ewald</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>E-cadherin is required for metastasis in multiple models of breast cancer</article-title><source>Nature</source><volume>573</volume><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1526-3</pub-id><pub-id pub-id-type="pmid">31485072</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastushenko</surname><given-names>I</given-names></name><name><surname>Brisebarre</surname><given-names>A</given-names></name><name><surname>Sifrim</surname><given-names>A</given-names></name><name><surname>Fioramonti</surname><given-names>M</given-names></name><name><surname>Revenco</surname><given-names>T</given-names></name><name><surname>Boumahdi</surname><given-names>S</given-names></name><name><surname>Van Keymeulen</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Moers</surname><given-names>V</given-names></name><name><surname>Lemaire</surname><given-names>S</given-names></name><name><surname>De Clercq</surname><given-names>S</given-names></name><name><surname>Minguijón</surname><given-names>E</given-names></name><name><surname>Balsat</surname><given-names>C</given-names></name><name><surname>Sokolow</surname><given-names>Y</given-names></name><name><surname>Dubois</surname><given-names>C</given-names></name><name><surname>De Cock</surname><given-names>F</given-names></name><name><surname>Scozzaro</surname><given-names>S</given-names></name><name><surname>Sopena</surname><given-names>F</given-names></name><name><surname>Lanas</surname><given-names>A</given-names></name><name><surname>D’Haene</surname><given-names>N</given-names></name><name><surname>Salmon</surname><given-names>I</given-names></name><name><surname>Marine</surname><given-names>J-C</given-names></name><name><surname>Voet</surname><given-names>T</given-names></name><name><surname>Sotiropoulou</surname><given-names>PA</given-names></name><name><surname>Blanpain</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of the tumour transition states occurring during EMT</article-title><source>Nature</source><volume>556</volume><fpage>463</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0040-3</pub-id><pub-id pub-id-type="pmid">29670281</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlova</surname><given-names>NN</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The hallmarks of cancer metabolism: Still emerging</article-title><source>Cell Metabolism</source><volume>34</volume><fpage>355</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2022.01.007</pub-id><pub-id pub-id-type="pmid">35123658</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sassa</surname><given-names>T</given-names></name><name><surname>Kihara</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Metabolism of very long-chain fatty acids: genes and pathophysiology</article-title><source>Biomolecules &amp; Therapeutics</source><volume>22</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.4062/biomolther.2014.017</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlaepfer</surname><given-names>IR</given-names></name><name><surname>Hitz</surname><given-names>CA</given-names></name><name><surname>Gijón</surname><given-names>MA</given-names></name><name><surname>Bergman</surname><given-names>BC</given-names></name><name><surname>Eckel</surname><given-names>RH</given-names></name><name><surname>Jacobsen</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel</article-title><source>Molecular and Cellular Endocrinology</source><volume>363</volume><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2012.08.005</pub-id><pub-id pub-id-type="pmid">22922095</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigetomi</surname><given-names>K</given-names></name><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Inai</surname><given-names>T</given-names></name><name><surname>Ikenouchi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Adherens junctions influence tight junction formation via changes in membrane lipid composition</article-title><source>The Journal of Cell Biology</source><volume>217</volume><fpage>2373</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1083/jcb.201711042</pub-id><pub-id pub-id-type="pmid">29720382</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigetomi</surname><given-names>K</given-names></name><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Matsuzawa</surname><given-names>K</given-names></name><name><surname>Ikenouchi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Cholesterol-rich domain formation mediated by ZO proteins is essential for tight junction formation</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2217561120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2217561120</pub-id><pub-id pub-id-type="pmid">36791108</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases</article-title><source>Cell Metabolism</source><volume>33</volume><fpage>1911</fpage><lpage>1925</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.09.001</pub-id><pub-id pub-id-type="pmid">34562355</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subczynski</surname><given-names>WK</given-names></name><name><surname>Pasenkiewicz-Gierula</surname><given-names>M</given-names></name><name><surname>Widomska</surname><given-names>J</given-names></name><name><surname>Mainali</surname><given-names>L</given-names></name><name><surname>Raguz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>High cholesterol/low cholesterol: effects in biological membranes: a review</article-title><source>Cell Biochemistry and Biophysics</source><volume>75</volume><fpage>369</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1007/s12013-017-0792-7</pub-id><pub-id pub-id-type="pmid">28417231</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szlasa</surname><given-names>W</given-names></name><name><surname>Zendran</surname><given-names>I</given-names></name><name><surname>Zalesińska</surname><given-names>A</given-names></name><name><surname>Tarek</surname><given-names>M</given-names></name><name><surname>Kulbacka</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lipid composition of the cancer cell membrane</article-title><source>Journal of Bioenergetics and Biomembranes</source><volume>52</volume><fpage>321</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1007/s10863-020-09846-4</pub-id><pub-id pub-id-type="pmid">32715369</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Klymchenko</surname><given-names>AS</given-names></name><name><surname>Tsurumaki</surname><given-names>E</given-names></name><name><surname>Ikenouchi</surname><given-names>J</given-names></name><name><surname>Konishi</surname><given-names>G-I</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Fluorescent solvatochromic probes for long-term imaging of lipid order in living cells</article-title><source>Advanced Science</source><volume>11</volume><elocation-id>e2309721</elocation-id><pub-id pub-id-type="doi">10.1002/advs.202309721</pub-id><pub-id pub-id-type="pmid">38468355</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Meer</surname><given-names>G</given-names></name><name><surname>Voelker</surname><given-names>DR</given-names></name><name><surname>Feigenson</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Membrane lipids: where they are and how they behave</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>9</volume><fpage>112</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/nrm2330</pub-id><pub-id pub-id-type="pmid">18216768</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Lokman</surname><given-names>NA</given-names></name><name><surname>Noye</surname><given-names>TM</given-names></name><name><surname>Macpherson</surname><given-names>AM</given-names></name><name><surname>Oehler</surname><given-names>MK</given-names></name><name><surname>Ricciardelli</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome</article-title><source>Cancer Drug Resistance</source><volume>4</volume><fpage>485</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.20517/cdr.2020.107</pub-id><pub-id pub-id-type="pmid">35582032</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Tao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Vitamin A deficiency results in dysregulation of lipid efflux pathway in rat kidney</article-title><source>Pediatric Nephrology</source><volume>25</volume><fpage>1435</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1007/s00467-010-1532-z</pub-id><pub-id pub-id-type="pmid">20480185</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Carstens</surname><given-names>JL</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Scheible</surname><given-names>M</given-names></name><name><surname>Kaye</surname><given-names>J</given-names></name><name><surname>Sugimoto</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>LeBleu</surname><given-names>VS</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer</article-title><source>Nature</source><volume>527</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/nature16064</pub-id><pub-id pub-id-type="pmid">26560028</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104374.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wakana</surname><given-names>Yuichi</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Tokyo University of Pharmacy and Life Sciences</institution><country>Japan</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd></kwd-group></front-stub><body><p>This article presents the <bold>fundamental</bold> discovery that lipid metabolic imbalance induced by Snail, an EMT-related transcription factor, contributes to the acquisition of chemoresistance in cancer cells. The evidence, supported by a wide range of methods and adequate quantification, provides a <bold>convincing</bold> mechanistic explanation of how Snail drives ectopic expression of the cholesterol- and drug-efflux transporter ABCA1. This work, which introduces a novel therapeutic concept targeting invasive cancer, will be of broad interest to researchers in cancer biology, lipid metabolism, and cell biology.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104374.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The authors focus on the molecular mechanisms by which EMT cells confer resistance to cancer cells. The authors use a wide range of methods to reveal that overexpression of Snail in EMT cells induces cholesterol/sphingomyelin imbalance via transcriptional repression of biosynthetic enzymes involved in sphingomyelin synthesis. The study also revealed that ABCA1 is important for cholesterol efflux and thus for counterbalancing the excess of intracellular free cholesterol in these snail-EMT cells. Inhibition of ACAT, an enzyme catalyzing cholesterol esterification, also seems essential to inhibit the growth of snail-expressing cancer cells.</p><p>Overall, the provided data are convincing and enhance our knowledge of cancer biology.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104374.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This revised study provides a clearer and more mechanistically grounded explanation of how lipid metabolic imbalance contributes to EMT-associated chemoresistance in renal cancer. In this study, the authors discovered that chemoresistance in RCC cell lines correlates with the expression levels of ABCA1 and the EMT-related transcription factor Snail. They demonstrate that Snail induces ABCA1 expression and chemoresistance, and that inhibition of ABCA1-associated pathways can counteract this resistance. The study also suggests that Snail disrupts the cholesterol-sphingomyelin balance by repressing enzymes involved in VLCFA-sphingomyelin synthesis, leading to excess free cholesterol and activation of the LXR-ABCA1 axis. Importantly, inhibiting cholesterol esterification, which renders free cholesterol inert, selectively suppresses growth of a xenograft model of Snail-positive kidney cancer. These findings provide potential lipid metabolism-targeting strategies for cancer therapy. The revised version includes additional quantitative analyses and new experiments addressing lipid balance and ABCA1 localization, further strengthening the overall mechanistic model.</p><p>Strengths:</p><p>This revised manuscript provides a more comprehensive and convincing mechanistic explanation for how Snail-driven EMT induces chemoresistance through altered lipid homeostasis. The study presents a novel concept in which the Chol/SM balance, rather than individual lipid levels, shapes therapeutic vulnerability. The potential for targeting cholesterol detoxification pathways in Snail-positive cancer cells remains a significant therapeutic implication. In the revised version, the authors provide additional quantitative analyses and complementary experiments - including ABCA1 localization, restoration of VLCFA-SM levels by supplementation with C22:0 ceramide, and membrane-order assays - which further strengthen the mechanistic interpretation and address key concerns raised in earlier reviews.</p><p>Weaknesses:</p><p>The revised version includes new experiments showing that restoring sphingomyelin levels suppresses ABCA1 expression, thereby strengthening the causal link between altered lipid balance and ABCA1 induction. However, the evidence that ABCA1 is directly required for chemoresistance remains somewhat limited, as the phenotype was not reproduced by ABCA1 knockout or knockdown, and CsA may affect additional targets beyond ABCA1.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104374.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Matsumoto</surname><given-names>Atsuhi</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Inoko</surname><given-names>Akihito</given-names></name><role specific-use="author">Author</role><aff><institution>Aichi Medical University</institution><addr-line><named-content content-type="city">Nagakute</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Takuya</surname><given-names>Tanaka</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Science Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Konishi</surname><given-names>Gen-Ichi</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Science Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Hosoda</surname><given-names>Waki</given-names></name><role specific-use="author">Author</role><aff><institution>Aichi Cancer Center Hospital</institution><addr-line><named-content content-type="city">Aichi</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Kojima</surname><given-names>Takahiro</given-names></name><role specific-use="author">Author</role><aff><institution>Aichi Cancer Center Hospital</institution><addr-line><named-content content-type="city">Aichi</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Ohnishi</surname><given-names>Koji</given-names></name><role specific-use="author">Author</role><aff><institution>Aichi Medical University School of Medicine</institution><addr-line><named-content content-type="city">Aichi</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Ikenouchi</surname><given-names>Junichi</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>The authors focus on the molecular mechanisms by which EMT cells confer resistance to cancer cells. The authors use a wide range of methods to reveal that overexpression of Snail in EMT cells induces cholesterol/sphingomyelin imbalance via transcriptional repression of biosynthetic enzymes involved in sphingomyelin synthesis. The study also revealed that ABCA1 is important for cholesterol efflux and thus for counterbalancing the excess of intracellular free cholesterol in these snail-EMT cells. Inhibition of ACAT, an enzyme catalyzing cholesterol esterification, also seems essential to inhibit the growth of snail-expressing cancer cells.</p><p>However, It seems important to analyze the localization of ABCA1, as it is possible that in the event of cholesterol/sphingomyelin imbalance, for example, the intracellular trafficking of the pump may be altered.</p><p>The authors should also analyze ACAT levels and/or activity in snail-EMT cells that should be increased. Overall, the provided data are important to better understand cancer biology.</p></disp-quote><p>We thank the reviewer for recognizing the significance of our study. Consistent with the hypothesis that ABCA1 contributes to chemoresistance in hybrid E/M cells, we agree that demonstrating the localization of ABCA1 at the plasma membrane is important, and we have included additional experiments to address this point.</p><p>We also examined the expression of the major ACAT isoform in the kidney, SOAT1, across RCC cell lines. However, its expression did not correlate with that of Snail (Figure 4B), suggesting that SOAT1 is constitutively expressed at a certain level regardless of Snail expression. The details of these additional experiments are provided in the point-by-point responses below.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>In this study, the authors discovered that the chemoresistance in RCC cell lines correlates with the expression levels of the drug transporter ABCA1 and the EMT-related transcription factor Snail. They demonstrate that Snail induces ABCA1 expression and chemoresistance, and that ABCA1 inhibitors can counteract this resistance. The study also suggests that Snail disrupts the cholesterol-sphingomyelin (Chol/SM) balance by repressing the expression of enzymes involved in very long-chain fatty acid-sphingomyelin synthesis, leading to excess free cholesterol. This imbalance activates the cholesterol-LXR pathway, inducing ABCA1 expression. Moreover, inhibiting cholesterol esterification suppresses Snail-positive cancer cell growth, providing potential lipid-targeting strategies for invasive cancer therapy.</p><p>Strengths:</p><p>This research presents a novel mechanism by which the EMT-related transcription factor Snail confers drug resistance by altering the Chol/SM balance, introducing a previously unrecognized role of lipid metabolism in the chemoresistance of cancer cells. The focus on lipid balance, rather than individual lipid levels, is a particularly insightful approach. The potential for targeting cholesterol detoxification pathways in Snail-positive cancer cells is also a significant therapeutic implication.</p><p>Weaknesses:</p><p>The study's claim that Snail-induced ABCA1 is crucial for chemoresistance relies only on pharmacological inhibition of ABCA1, lacking additional validation. The causal relationship between the disrupted Chol/SM balance and ABCA1 expression or chemoresistance is not directly supported by data. Some data lack quantitative analysis.</p></disp-quote><p>We thank the reviewer for his/her insightful and constructive comments. In response, we have performed additional experiments using complementary approaches to further substantiate the contribution of Snail-induced ABCA1 expression to chemoresistance. Furthermore, to clarify the causal relationship between reduced sphingomyelin biosynthesis and ABCA1 expression, we conducted new experiments showing that supplementation with sphingolipids attenuates ABCA1 upregulation (Figure 3H). The details of these additional experiments are described in the point-by-point responses below.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>In this paper, the authors reveal that snail expression in EMT-cells leads to an imbalance between cholesterol and sphingomyelin via a transcriptional repression of enzymes involved in the biosynthesis of sphingomyelin.</p><p>This paper is interesting and highlights how the imbalance of lipids would impact chemotherapy resistance. However, I have a few comments.</p><p>In Figure 2 in Eph4 cells, while filipin staining appears exclusively at the plasma membrane in the case of EpH4-snail cells filipin staining is also intracellular. It seems plausible that all filipin-positive intracellular staining is not exclusively in LDs, authors should therefore try to colocalize filipin with other intracellular markers. To this aim, authors might want to use topfluocholesterol-probe for instance.</p></disp-quote><p>We examined the distribution of TopFluor-cholesterol in hybrid E/M cells (Figure 2H) and found that TopFluor-cholesterol colocalizes with lipid droplets. In addition, we analyzed the colocalization between intracellular filipin signals and organelle-specific proteins, ADRP (lipid droplets) and LAMP1 (lysosomes) (Figure 2I). Since filipin binds exclusively to unesterified cholesterol, filipin signals did not colocalize with ADRP. Instead, we observed colocalization of filipin with LAMP1, suggesting that cholesterol accumulates in hybrid E/M cells in both esterified and unesterified forms.</p><disp-quote content-type="editor-comment"><p>In Figure 3, the authors reveal that the exogenous expression of the snail alters the ratio of cholesterol to sphingomyelin. The authors should reveal where is found the intracellular cholesterol and intracellular sphingomyelin within these cells Eph4-snail.</p></disp-quote><p>To investigate the lipid composition of the plasma membrane, we utilized lipid-binding protein probes, D4 (for cholesterol) and lysenin (for sphingomyelin) (Figures 2L and 2M). We found that the plasma membrane cholesterol content was not affected by EMT, whereas sphingomyelin levels were markedly decreased. In addition, intracellular cholesterol was visualized (Comment 1-1; Figures 2E–2K). On the other hand, because visualization of intracellular sphingomyelin is technically challenging, we were unable to include this analysis in the present study. We consider this an important direction for future investigation.</p><disp-quote content-type="editor-comment"><p>Regarding the model described in panel K of Figure 3. I would expect that the changes in lipid-membrane organization depicted in panel K should affect the pattern of GM1 toxin for instance or the motility of raft-associated proteins for instance. The authors could perform these experiments in order to sustain the change of lipid plasma membrane organization.</p></disp-quote><p>We attempted staining with FITC–cholera toxin to visualize GM1, but both EpH4 and EpH4–Snail cells exhibited very low levels of GM1, resulting in minimal or no detectable staining (data not shown). Instead, to assess the impact of decreased sphingomyelin on the overall biophysical properties of the plasma membrane, we used a plasma membrane–specific lipid-order probe, FπCM–SO₃ (Figures 2N–2P and Figure 2—figure supplement 3). We found that the plasma membrane of EpH4–Snail cells was more disordered (fluidized), suggesting that the overall properties of the plasma membrane are altered by ectopic expression of Snail.</p><disp-quote content-type="editor-comment"><p>Another issue is the intracellular localization of ABCA1 in Eph4-Snail cells. Knowing that a change in the cholesterol/sphingomyelin ratio can also modify intracellular protein trafficking, it seems important to analyze the intracellular localization of ABCA1 in EPh4-Snail cells.</p></disp-quote><p>We performed immunofluorescence microscopy for ABCA1 and found that ABCA1 was mainly localized at the plasma membrane in EpH4–Snail cells (Figure 1M).</p><disp-quote content-type="editor-comment"><p>As for the data on ACAT inhibition, we expect an increase in ACAT activity and protein levels in EMT cells overexpressing Snail. The authors should also investigate this point.</p></disp-quote><p>As noted in our response to the public review, we examined the expression of the major ACAT isoform in the kidney, SOAT1, across RCC cell lines. However, its expression did not correlate with Snail (Figure 4B), suggesting that SOAT1 is expressed at sufficient levels even in cells with low Snail expression. We agree that measuring ACAT activity would be important, as ACATs are regulated at multiple levels. However, we consider this to be beyond the scope of the present study and plan to address it in future work.</p><disp-quote content-type="editor-comment"><p>Minor comments</p><p>I do not understand why in the text, Figure S1 appears after Figure S2. The authors might want to change the numbering of these two figures.</p></disp-quote><p>We thank the reviewer for pointing this out. We have corrected the numbering of the supplementary figures so that Figure S1 now appears before Figure S2 in both the text and the revised figure legends.</p><disp-quote content-type="editor-comment"><p>Page 5, lane 20 Figure 1I instead of 1H.</p><p>Page 6, lane 2, Figure 1J instead of 1I, and lane 9 Figure 1H instead of 1I.</p></disp-quote><p>We thank the reviewer for carefully checking the figure references. We have corrected the figure numbering errors in the text as suggested.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>For Figures 1B, 1H, 1J, 2B, 2C, 3G, S3A, and S3B, to enhance data reliability, it is necessary to conduct a quantitative analysis of the Western blot data. The average values from at least three biological replicates should be calculated, with statistical significance assessed.</p></disp-quote><p>We have conducted quantitative analyses of the Western blot data for Figures 1B, 1H, 1J, 2B, 2C, 3G, S3A, and S3B. Band intensities from at least three independent biological replicates were quantified, and the mean values with statistical significance are now presented in the revised figures.</p><disp-quote content-type="editor-comment"><p>For Figures 1D, 2A, 2D, and S2, the images of cells or tissues should not rely solely on selected fields. Quantitative analysis is required, and the mean values from at least three biological replicates should be provided with statistical significance testing.</p></disp-quote><p>We have performed quantitative analyses for Figures 1D, 2A, 2D, and S2. The quantification was based on data from at least three independent biological replicates, and the mean values with statistical significance are now included in the revised figures.</p><disp-quote content-type="editor-comment"><p>For Figures 1A, 1G, 4, and S5, evaluating ABCA1's involvement in drug resistance based solely on CsA treatment is insufficient. Demonstrating the loss of drug resistance through ABCA1 knockdown or knockout is necessary.</p></disp-quote><p>We generated ABCA1 knockout EpH4–Snail cells and examined their resistance to nitidine chloride. However, knockout of ABCA1 alone did not affect resistance to the compound (Figure 2 - figure supplement 2). This may be due to secondary metabolic alterations induced by ABCA1 loss or compensatory upregulation of other LXR-induced cholesterol efflux transporters. Instead, we demonstrated that treatment with the LXR inhibitor GSK2033 reduced the nitidine chloride resistance of EpH4–Snail cells (Figure 2C), supporting the idea that enhanced efflux of antitumor agents through the LXR–ABCA1–mediated cholesterol efflux pathway contributes to nitidine chloride resistance.</p><disp-quote content-type="editor-comment"><p>For Figure 3, to establish a causal relationship between changes in the Chol/SM balance and ABCA1 expression, it is important to test whether modifying cholesterol and SM levels to disrupt this balance affects ABCA1 expression.</p></disp-quote><p>Regarding causality, as shown in Figure 2, we have already demonstrated that reducing cholesterol levels in EpH4–Snail cells decreases ABCA1 expression. To further explore this relationship, we examined whether increasing sphingomyelin levels by adding ceramide to the culture medium—thereby restoring the sphingomyelin-to-cholesterol ratio—would reduce ABCA1 expression (Figure 3H). Indeed, supplementation with C22:0 ceramide decreased ABCA1 expression, suggesting that downregulation of the VLCFA-sphingomyelin biosynthetic pathway triggers ABCA1 upregulation. Collectively, these findings support a causal relationship between the Chol/SM balance and ABCA1 expression.</p><disp-quote content-type="editor-comment"><p>In Figure 3, if there is any information on differences in cholesterol affinity between LCFA-SM and VLCFA-SM, it would be beneficial to include it in the manuscript.</p></disp-quote><p>Differences in cholesterol affinity between LCFA-SM and VLCFA-SM in cellular membranes remain controversial and have yet to be fully elucidated. The decrease in cell surface sphingomyelin content, evaluated by lysenin staining (Figure 2L), was more pronounced than that of total sphingomyelin (Figure 3A). Given that VLCFA-SMs have been suggested to undergo distinct trafficking during recycling from endosomes to the plasma membrane (Koivusalo et al. Mol Biol Cell 2007), their reduction may lead to decreased plasma membrane sphingomyelin content by altering its intracellular distribution. We have added this discussion to the revised manuscript.</p><disp-quote content-type="editor-comment"><p>In Figure 3F, it is recommended to assess housekeeping gene expression as a control. Quantitative real-time PCR should be performed, and the average values from at least three biological replicates should be presented.</p></disp-quote><p>We have performed quantitative RT-PCR analysis. The average values from at least three independent biological replicates are presented in Figure 3G.</p><disp-quote content-type="editor-comment"><p>For Figure 3F, to show whether the reduction of CERS3 or ELOVL7 affects the Chol/SM balance and ABCA1 expression, it is necessary to investigate the phenotypes following the knockdown or knockout of these enzymes.</p></disp-quote><p>We fully agree that phenotypic analyses of epithelial cells lacking CerS3 or ELOVL7 would provide valuable insights. However, we consider such investigations to be beyond the scope of the present study and plan to pursue them in future work.</p><disp-quote content-type="editor-comment"><p>Clarifying whether similar phenotypes are induced by other EMT-related transcription factors, or if they are specific to Snail, would be beneficial.</p></disp-quote><p>We agree that examining whether similar phenotypes are induced by other EMT-related transcription factors would be highly valuable for understanding the broader EMT network. However, as the focus of the present study is on lipid metabolic alterations associated with EMT—particularly the imbalance between sphingomyelin and cholesterol—we consider this investigation to be beyond the scope of the current work and plan to address it in future studies.</p><disp-quote content-type="editor-comment"><p>There are errors in figure citations within the text that need correction:</p><p>p.9 l.18 Fig. 3D → Fig. 3G</p><p>p.9 l.22 Fig. 3I → Fig. 3H</p><p>p.9 l.23 Fig. S2 → Fig. S4</p><p>p.10 l.6 Fig. 3J → Fig. 1J</p><p>p.10 l.8 Fig. 3J → Fig. 1J</p><p>p.10 l.9 Fig. 3K → Fig. 3I</p><p>p.10 l.12 Fig. 3H → Fig. 3J</p><p>p.10 l.14 Fig. 2D and Fig. S4 → Fig. 2G and Fig. S4D</p></disp-quote><p>We thank the reviewer for carefully pointing out these citation errors. We have corrected all figure references in the text as suggested.</p></body></sub-article></article>